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ARTICLE

The human CIB1–EVER1–EVER2 complex
governs keratinocyte-intrinsic immunity to
β-papillomaviruses
Sarah Jill de Jong1, Amandine Créquer1*, Irina Matos2*, David Hum1*, Vignesh Gunasekharan3, Lazaro Lorenzo4,5, Fabienne Jabot‑Hanin4,5,
Elias Imahorn6, Andres A. Arias7,8, Hassan Vahidnezhad9,10, Leila Youssefian9,11, Janet G. Markle1, Etienne Patin12,13,14, Aurelia D’Amico1,
Claire Q.F. Wang15, Florian Full16, Armin Ensser16, Tina M. Leisner17, Leslie V. Parise17, Matthieu Bouaziz4,5, Nataly Portilla Maya18,
Xavier Rueda Cadena19, Bayaki Saka20, Amir Hossein Saeidian9, Nessa Aghazadeh21, Sirous Zeinali10,22, Peter Itin6,23, James G. Krueger15**,
Lou Laimins3**, Laurent Abel1,4,5***, Elaine Fuchs2***, Jouni Uitto9,24***, Jose Luis Franco7****, Bettina Burger6****, Gérard Orth25*****,
Emmanuelle Jouanguy1,4,5*****, and Jean‑Laurent Casanova1,4,5,26,27*****

Patients with epidermodysplasia verruciformis (EV) and biallelic null mutations of TMC6 (encoding EVER1) or TMC8 (EVER2)
are selectively prone to disseminated skin lesions due to keratinocyte-tropic human β-papillomaviruses (β-HPVs), which lack
E5 and E8. We describe EV patients homozygous for null mutations of the CIB1 gene encoding calcium- and integrin-binding
protein-1 (CIB1). CIB1 is strongly expressed in the skin and cultured keratinocytes of controls but not in those of patients.
CIB1 forms a complex with EVER1 and EVER2, and CIB1 proteins are not expressed in EVER1- or EVER2-deficient cells. The
known functions of EVER1 and EVER2 in human keratinocytes are not dependent on CIB1, and CIB1 deficiency does not impair
keratinocyte adhesion or migration. In keratinocytes, the CIB1 protein interacts with the HPV E5 and E8 proteins encoded
by α-HPV16 and γ-HPV4, respectively, suggesting that this protein acts as a restriction factor against HPVs. Collectively,
these findings suggest that the disruption of CIB1–EVER1–EVER2-dependent keratinocyte-intrinsic immunity underlies the
selective susceptibility to β-HPVs of EV patients.

Introduction

Epidermodysplasia verruciformis (EV; OMIM ID 226400) is a
rare Mendelian genodermatosis. EV patients are highly and selectively susceptible to skin diseases due to cutaneous human
papillomaviruses (HPVs) of the β genus (Orth, 2006, 2008; de
Jong et al., 2018). They are otherwise healthy and normally re-

sistant to other microorganisms including other viruses and
skin-tropic pathogens and even all other cutaneous and mucosal
HPVs. Early in childhood, these patients present with persistent,
disseminated, flat warts and pityriasis versicolor–like lesions
of the skin that are induced by β-HPVs. Some patients develop
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nonmelanoma skin cancer, particularly on areas of the body exposed to the sun. By contrast, β-HPV infection is widespread and
asymptomatic in the general population. EV is transmitted as an
autosomal recessive (AR) trait in most families but was shown
to be X-linked recessive in one family (Androphy et al., 1985).
Biallelic null mutations of either TMC6 or TMC8 encoding EVER1
and EVER2, respectively, account for about half the patients and
families displaying EV (Ramoz et al., 2002; Burger and Itin, 2014;
Imahorn et al., 2017; de Jong et al., 2018). These genes are widely
expressed throughout the body, including in leukocytes, but
patients with null mutations display no consistent abnormalities of the development or function of any subset of leukocytes
(Lazarczyk et al., 2012; Crequer et al., 2013). EVER1 or EVER2
deficiency in keratinocytes, which would normally express both
proteins and are the natural and exclusive host cells of β-HPVs,
has thus been proposed as the cellular basis of the disease (Orth,
2006, 2008). The exceedingly narrow infectious phenotype and
the lack of detectable leukocyte abnormalities prevented EV
from being recognized as a primary immunodeficiency until
the discovery of genetic etiologies in 2002 (Ramoz et al., 2002;
Notarangelo et al., 2004; Casanova, 2015a,b). However, EV was
shown to be an inborn error underlying viral lesions between
1922 and 1946 by the works of Wilhelm Lutz and Edward Cockayne (Lewandowsky and Lutz, 1922; Cockayne, 1933; Lutz, 1946),
before the first descriptions of congenital neutropenia by Ralph
Kostmann and inherited agammaglobulinemia by Ogden Bruton
(Kostmann, 1950; Bruton, 1952).
Patients with an “atypical” form of inherited EV have recently
been described (de Jong et al., 2018). These patients suffer from
primary immunodeficiencies due to profound T cell defects
caused by inactivating biallelic mutations of STK4 (Crequer et al.,
2012a), RHOH (Crequer et al., 2012b), CORO1A (Stray-Pedersen
et al., 2014), TPP2 (Stepensky et al., 2015), DCLRE1C (Tahiat et al.,
2016), LCK (Li et al., 2016), RASGRP1 (Platt et al., 2017), or DOCK8
(Sanal et al., 2012; Liu et al., 2017). Other patients with atypical
EV have T cell deficits of unknown genetic etiology (Azzimonti et
al., 2005; Borgogna et al., 2014; Landini et al., 2014). In all these
patients, persistent infection with β-HPVs causes skin lesions
identical to those of patients with classic EV, but in a context of
broader infectious manifestations, the breadth and severity of
which depend on the mutated gene and the nature of the T cell
deficit. Indeed, patients with inherited T cell deficiencies typically suffer from various viral, bacterial, fungal, and parasitic
infections, including many infections of the skin and viral infections in particular (Notarangelo et al., 2004; Fischer, 2015).
These patients are also prone to various autoimmune and, more
rarely, tumoral manifestations. An additional role of these gene
products in keratinocytes has not been formally excluded, but
the T cell deficit common to all these patients strongly suggests
that full T cell development and function are required for protective immunity to β-HPVs. Intriguingly, not all T cell deficits
seem to confer a predisposition to β-HPV–driven lesions, and
not all patients with such deficits display lesions of this type.
Finally, β-HPV–induced skin lesions resembling typical EV have
also been reported in a third group of patients who are otherwise
healthy years after successful allogeneic hematopoietic stem cell
transplantation (HSCT) for severe combined immunodeficiency
de Jong et al.
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due to mutations of IL2RG and JAK3 (Laffort et al., 2004). As
both these genes are also normally expressed in keratinocytes,
this third type of EV might be caused by a persistent deficiency
of their products in keratinocytes that is not corrected by allogeneic HSCT. The products of these genes may be physiologically
connected with EVER1 and EVER2 in keratinocytes.
The molecular basis of “typical” EV remains elusive. One plausible hypothesis is that β-HPVs are defective for a growth-promoting function encoded by the E5 gene, located between the
E2-L2 genes of cutaneous α-HPVs, or the E8 gene, located in the
E6 region of γ-, κ-, and μ-papillomaviruses, and that EVER1/2
deficiency may compensate for the missing viral function (Bravo
and Alonso, 2004; Nonnenmacher et al., 2006; Orth, 2006,
2008). Indeed, it has been shown in vivo that cottontail rabbit
papilloma virus (CRPV)-E8 is essential for the development of
lesions in rabbits (Hu et al., 2002; Nonnenmacher et al., 2006).
EVER1 and EVER2 belong to a larger family of transmembrane
channel–like (TMC) proteins (Keresztes et al., 2003; Kurima
et al., 2003). TMC1 and TMC2 are components of the sensory
transduction ion channel in inner ear hair cells (Kawashima et
al., 2011; Pan et al., 2013; Kurima et al., 2015). Both TMC6 and
TMC8 are broadly expressed in human tissues, but expression
levels are generally lower for TMC8 (www.proteinatlas.org). No
knockout mice have been reported for either of these genes. It has
been suggested that EVER1 and EVER2 control intracellular zinc
homeostasis in human leukocytes and keratinocytes through interaction with the ER-resident zinc transporter ZnT1 (Lazarczyk
et al., 2008, 2009, 2012). HPV16-E5α (E5α being encoded by mucosal and E5β by cutaneous HPVs) has been shown to interact
with EVER1/2 (Lazarczyk et al., 2008), and both HPV16-E5α and
E8 from CRPV interact with ZnT1 (Nonnenmacher et al., 2006;
Lazarczyk et al., 2008). It has also been suggested that EVER2
modulates TNF receptor signaling in human keratinocytes (Gaud
et al., 2013; Vuillier et al., 2014). The pathogenesis of EV-like lesions in patients with IL2RG and JAK3 mutations years after successful HSCT also remains unknown. Overall, the pathogenesis
of β-HPV–driven lesions in EVER1- and EVER2-deficient patients
and the mechanisms by which human keratinocytes normally
control β-HPVs remain unexplained. We investigated patients
with typical EV but no mutations of TMC6 or TMC8. We hypothesized that the discovery of novel genetic etiologies of EV might
open up new avenues of investigation into the pathogenesis of EV
and the interaction between human keratinocytes and β-HPVs.

Results

Clinical features of EV patients
We investigated 24 individuals with unexplained typical EV (P1–
P24) from six families originating from and living in five different countries (Colombia, France, Iran, Switzerland, and Togo;
Fig. 1 A). None of the patients carried mutations in the exons and
flanking intron regions of TMC6 or TMC8. The cohort was clinically homogeneous, with disseminated β-HPV–positive skin lesions at various sites on the body beginning in childhood or early
adulthood (Table 1 and Fig. S1). β-HPV5 and/or -HPV8 genotypes
have been identified in the lesions of all patients tested (12 of 24).
Cutaneous squamous cell carcinoma (SCC) developed in 14 of the
Journal of Experimental Medicine
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Figure 1. Identification of homozygous
mutations affecting human CIB1 in a cohort
of 24 EV patients. (A) Pedigrees of six kindreds
affected by EV. Familial segregation of homozygous CIB1 mutations (m/m) in six consanguineous families indicating an AR pattern of
inheritance with complete clinical penetrance.
(B) Graphical representation of the CIB1 cDNA
exon (c.CIB1) and protein (p.CIB1) structure
with presentation of the EF-hand domains. The
arrows at the top indicate the location of the
cDNA positions affected by the CIB1 mutations
found in the families, whereas those at the
bottom indicate their consequences at protein
level. *, stop codon; del, deletion; ins, insertion;
fs, frameshift.

24 patients, mostly on sun-exposed areas of the skin (Table 1). 12
of the 24 patients died: two from disseminated skin cancer (at
the ages of 71 yr for P13 and 21 yr for P16) and 10 from causes
unrelated to EV (aged 47–91 yr). None of the patients displayed
any other unusually severe infectious diseases despite exposure
to a large number of different infectious agents in urban or rural
areas of countries as diverse as Colombia, France, Iran, Switzerland, and Togo. The clinical features of all patients other than
kindred F from Iran have been described in detail elsewhere with
the confirmation of β-HPV genotype and/or typical histological
signs of β-HPV infection (Lutz, 1946; Rueda and Rodriguez, 1976;
Kienzler et al., 1979; Kremsdorf et al., 1984; Deau et al., 1991, 1993;
Rueda, 1993; Saka et al., 2009; Arnold et al., 2011; Imahorn et al.,
2017). Case studies for all 24 patients are listed in Materials and
methods. P13 and P14 were among the first EV patients to be
documented by Wilhelm Lutz in 1946 (Lutz, 1946). Overall, these
patients were clinically and virologically indistinguishable from
patients with biallelic truncating mutations of TMC6 or TMC8,
with an AR but unexplained inheritance of lesions due to β-HPVs.
Immunological features of EV patients
Immunophenotyping of the patients tested (P3, P5, P15, P16, and
P17) revealed normal numbers and compartmentalization of circulating T cells, B cells, and NK cells (Table S1) as in patients carrying homozygous inactivating mutations of TMC8 (Crequer et
al., 2013). Furthermore, T cell function after CD3 stimulation (P3
and P5; Table S2) and B cell function as measured by antibody responses to common DNA and RNA viruses (P1–P5; Table S3) were
normal. This finding is also consistent with those for patients
de Jong et al.
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with EVER2 deficiency (Crequer et al., 2013) but not for patients
with RHOH, MST1, CORO1A, ARTEMIS, RASGRP, DOCK8, and
TPP2 deficiencies who suffer from CD4+ T cell lymphopenia and
various degrees of impairment of circulating T cell response to
CD3 stimulation (Crequer et al., 2012a,b; Sanal et al., 2012; StrayPedersen et al., 2014; Stepensky et al., 2015; Tahiat et al., 2016;
Liu et al., 2017; Platt et al., 2017). Finally, more detailed analyses
of skin-homing T cell populations (CLA+, CCR10+, CLA+CCR4+,
and CLA+CCR10+ subsets) revealed no frequency abnormalities
in the five patients tested (P1–P4 and P15; Table S4), again contrasting with the smaller sizes of these subsets within the CD4+
compartment in RHOH-deficient patients (Table S4; Crequer et
al., 2012b). These skin-homing subsets even displayed mild expansion in three EVER2-deficient patients (Crequer et al., 2013).
Thus, none of the patients tested displayed any detectable lymphocyte abnormalities, suggesting that they suffer from a new AR
genetic etiology of EV affecting keratinocyte-intrinsic immunity
as in EVER1- and EVER2-deficient patients.
Identification of a 2.4-Mb chromosomal region by genomewide linkage (GWL)
We used GWL analyses to search for genetic etiologies of EV in
this cohort. Kindreds A, D, E, and F were known to be consanguineous, and consanguinity was suspected for kindreds B and
C. We confirmed that all patients were born to consanguineous
parents (Table S5) by showing that their inbreeding coefficients,
as estimated with FSuite (Gazal et al., 2014) and genotyping
data obtained with the Affymetrix Genome-wide Human Single Nucleotide Polymorphism (SNP) or Illumina Infinum Global
Journal of Experimental Medicine
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Table 1. Comparison of the clinical phenotypes of the 24 EV patients described in this study
Patient

Case

Sex

Age (yr)

Age onset (yr)/SCC

HPV type

Skin lesions (location)

SCC

Reference

P1

A1.viii.4

F

50

12/no

Unknown

Head and hands

No

Rueda (1993)

P2

A1.viii.7

M

47*

6/18

8, 17, 20

Head, neck, trunk, hands, legs,
and feet

Forehead

Rueda (1993), case 11

P3

A1.viii.10

F

46

7/13

8, 20

Head, trunk, legs, arms, and
hands

Forehead, lips

Rueda (1993), case 12

P4

A1.viii.12

F

44

7/no

8

Head and trunk

No

Rueda (1993)

P5

A1.viii.15

M

37

5/17

8, 20

Head, trunk, hands, and upper
legs

Forehead

Rueda (1993), case 13

P6

A1.vi.13

M

47*

1/15

Unknown

Head, trunk, hands, and legs

Nose, trunk

Rueda (1993), case 6

P7

A1.viii.30

M

47

5/10

5, 17, 36

Head, trunk, arms, hands, and
legs

Canthus, nose

Rueda (1993), case 7

P8

A2.ii.1

F

78*

1/47

5, 8, 20, 24

Head, trunk, and extremities

Forehead

Rueda (1993) and Rueda and
Rodriguez (1976), case 1 both
papers

P9

A2.ii.10

F

Unknown

5/38

8, 9

Head, trunk, and extremities

-

Rueda (1993) and Rueda and
Rodriguez (1976), case 2 both
papers

P10

A2.ii.12

M

48*

1/26

Unknown

Head, trunk, and extremities

Forehead, lips

Rueda (1993) and Rueda and
Rodriguez (1976), case 3 both
papers

P11

A2.ii.13

M

47*

3/27

5, 8, 20

Head, trunk, and extremities

Forehead

Rueda (1993) and Rueda and
Rodriguez (1976), case 4 both
papers

P12

B.ii.2

M

72*

23/43

8, 15

Head, trunk, arms, hands, and
legs

Forehead, check, ear Kienzler et al. (1979)

P13

C.ii.1

F

71*

Childhood/35

5

Head, neck, hands, and legs

Scalp, nose

Lutz (1946) and Arnold et al.
(2011), case 1 both papers

P14

C.ii.2

F

91*

<7/52

5

Head, neck, and hands

Nose, hand, neck,
forehead, scalp

Lutz (1946) and Arnold et al.
(2011), case 2 both papers

P15

D.iv.2

F

59

Childhood/54

5

Head, neck, arms, hand, knee,
and lower leg

Forehead, nose

Imahorn et al. (2017)

P16

E.iv.4

F

21*

7/unknown

Unknown

Face and trunk

Multiple (sunexposed skin)

Saka et al. (2009)

P17

E.iv.6

F

Unknown*

5/unknown

Unknown

Face and trunk

Unknown

Saka et al. (2009)

P18

E.iv.8

F

Unknown*

Unknown/unknown

Unknown

Unknown

Unknown

Saka et al. (2009)

P19

E.iv.10

M

14

2/unknown

Unknown

Face and trunk

Unknown

Saka et al. (2009)

P20

F.v.2

M

47

3/46

Unknown

Head, neck, trunk, and upper
and lower limb

Forehead
(basosquamous
carcinoma)

This study

P21

F.v.3

M

44

2/no

Unknown

Head, neck, trunk, and upper
and lower limb

-

This study

P22

F.v.7

F

30

5/no

Unknown

Head, neck, trunk, and upper
and lower limb

-

This study

P23

F.vi.1

F

22

1/no

Unknown

Head, neck, trunk, and upper
and lower limb

-

This study

P24

F.vi.2

M

21

4/no

Unknown

Head, neck, trunk, and upper
and lower limb

-

This study

Information collected from listed references or oral communication with the treating physicians. Please see Fig. 1 A for individual deidentifiers. F, female;
M, male; ages of death are marked with asterisks.

Screening array, were high. GWL analysis was performed by homozygosity mapping on 22 members of two branches (termed A1
and A2; Fig. 1 A) of the extended kindred A, P12 from kindred B,
P14 from kindred C, P15 from kindred D, six members of kindred
E, and four members of kindred F in two generations. A highly
significant linkage peak was found on chromosome 15, with a logarithm of odds (LOD) score of 16.7 for a 2.4-Mb interval (Fig. S2,
de Jong et al.
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A and B), strongly suggesting genetic homogeneity across these
kindreds. We then searched for allelic homogeneity by looking at
the haplotypes common to the various families. Kindred A is an
extended family with two branches: A1 and A2 (Fig. 1 A). These
two branches originate from the same region of Colombia and
are homozygous for the same 3.5-Mb haplotype encompassing
the linked interval, consistent with a common ancestral mutaJournal of Experimental Medicine
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tion. Kindreds C and D were not known to be related, but both
are from Switzerland, albeit from different cantons. These two
families share the same short homozygous 1.74-Mb haplotype encompassing the linked interval, suggesting a common ancestral
mutation for these two Swiss families. The shared haplotype of
kindreds C and D is part of the common haplotype of the Colombian patients. These findings reduce the interval of interest on
chromosome 15 to 1.74 Mb between positions 89.8 and 91.5 Mb.
Overall, these results strongly suggest that the 24 patients from
these six families have the same AR genetic etiology of EV, different from EVER1 and EVER2 deficiency, as the corresponding
genes TCM6 and TCM8, which are organized in tandem, are absent from this interval.
Identification of bi-allelic mutations of CIB1
We then performed whole-exome sequencing (WES) on the
probands from kindreds A–C and E (P7, P12, P14, and P19) and
four patients from kindred F (P20–P23; Figs. 1 A and S2 C). This
analysis identified CIB1 (encoding calcium- and integrin-binding
protein 1; CIB1) as the only gene carrying a very rare homozygous nonsynonymous coding mutation (minor allele frequency
[MAF] < 0.001) in all patients tested. CIB1 is located within the
1.74-Mb interval detected by GWL and homozygosity mapping,
which contains 33 other protein-coding genes and nine RNA
genes. In particular, no other gene within the interval of interest
on chromosome 15 was homozygous for rare nonsynonymous
coding variants common to all patients. The coding exons of the
42 genes were all fully covered by WES. Sanger sequencing of
genomic DNA confirmed that all 24 patients from the six kindreds were homozygous for CIB1 mutations (m/m), whereas the
34 unaffected family members tested were either heterozygous
(wt/m) or homozygous for the WT (wt/wt) allele (Figs. 1 A and
S2 D). The mutations were frameshift insertions (P1–P11, kindred A: c.465_465+1insG; P12, kindred B: c.549_550insTT) and
deletions (P13–15, kindred C and D: c.248_249delAA) predicted
to cause premature stop codons (P1–P11: p.I156Dfs*5; P13–15:
p.K83Rfs*4) or a stop loss (P12: p.A184Lfs*70), a nonsense allele
(P16–P19, kindred E: c.214C>T, p.R72*), and an essential splice site
mutation (P20–P24, kindred F: c.52-2A>G; Fig. 1 B) predicted by
the Genscan algorithm (Burge and Karlin, 1997) to eliminate the
acceptor site of exon 2 and to activate a cryptic acceptor site in
intron 1. This would result in the retention of 319 bp of intron 1
and the creation of a 47-aa protein product from exon 1 (aa 1–17)
and part of intron 1 followed by a stop codon (aa 18–47). All 24
patients from these six kindreds were homozygous for very rare
mutations of CIB1 and had no other homozygous genetic lesion
in common. Moreover, the segregation of the mutant alleles suggested an AR trait with complete penetrance as in families with
EVER1 or EVER2 deficiency.
The CIB1 mutations are predicted to be deleterious
The frameshift indels and splice-site mutations were not found
in the public databases Genome Aggregation Database (gnomAD;
Lek et al., 2016), Bravo (https://bravo.sph.umich.edu/freeze5/
hg38/), or the Greater Middle East variome project (http://igm
.ucsd.edu/gme/; Scott et al., 2016), and they were also absent
from our own in-house database of >4,500 exomes. The nonde Jong et al.
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sense R72* variant (dbSNP accession number rs143773090) was
found in four heterozygous individuals from the total of 276,936
individuals for whom data were available in the gnomAD, indicating an allele frequency of <1.4 × 10−5, consistent with the very
low prevalence of EV. Furthermore, no homozygous CIB1 nonsense or frameshift mutations were present in these public or
in-house databases. The gene-damage index (Itan et al., 2015) of
CIB1 is very low (1.131). Mutations of CIB1 predicted to be deleterious, with a combined annotation-dependent depletion (CADD)
score above the CIB1-specific mutation significance cutoff of 2.3
(Kircher et al., 2014; Itan et al., 2016), are very uncommon in the
general population, particularly in the homozygous state (only
three missense mutations, each with a MAF <0.0027). The CADD
scores of the CIB1 variants from the EV patients (35 for the insertions, 27.7 for the deletion, 24.8 for the essential splice, and 40 for
the nonsense variants) were well above the mutation significance
cutoff. These genetic findings strongly suggest that these CIB1
mutations, which are very rare or private to the six kindreds, are
deleterious. Their strict unique recessive linkage with EV unambiguously demonstrates that homozygosity for deleterious CIB1
alleles is a new AR genetic etiology of EV.
Lack of CIB1 expression in patients’ cells
The CIB1 protein is ubiquitous throughout the body and was first
identified as an intracellular regulator of integrin signaling in
platelets on the basis of its calcium-binding EF-hand domains
(Fig. 1 B). Human CIB1 has since emerged as a regulator of diverse
cellular processes including migration, adhesion, proliferation,
and cell death/survival (Leisner et al., 2016; Wang et al., 2017). We
first assessed the biochemical impact of the mutations by measuring endogenous CIB1 mRNA and protein levels in leukocytes.
Lymphoblastoid cell lines (LCLs) from P1–P5 and P7 had much
lower levels of CIB1 mRNA than those from WT family members
(wt/wt), whereas heterozygous (wt/m) family members had intermediate RNA levels (Fig. 2 A). The stop-loss mutation in P12
is predicted to lead to an elongated transcript. The levels of CIB1
mRNA in LCLs from P12 were higher than those for kindred A but
much lower than those for WT controls (Fig. 2 A). P13 also had
very low CIB1 mRNA levels in whole blood (Fig. 2 A), potentially
reflecting nonsense-mediated mRNA decay due to the presence
of premature stop codons. An antibody raised against an N-terminal epitope of CIB1 located upstream from all the premature
stop codons seen in the patients detected no endogenous CIB1
protein in LCLs or peripheral blood mononuclear cells (PBMCs)
from patients from kindreds A, B, and E, whereas CIB1 protein
was detected in unrelated controls and healthy family members (whether WT homozygous or heterozygous for the mutant
alleles; Fig. 2 B). Thus, all the CIB1 mutations tested greatly decreased mRNA levels and resulted in a complete absence of CIB1
protein from the cells tested. These data indicate that the patients
had AR complete CIB1 deficiency.
CIB1 is expressed in keratinocytes
The ubiquitous pattern of expression and the pleiotropic functions assigned to CIB1 are not easy to reconcile with the very
narrow clinical phenotype of EV patients. β-HPVs have a strict
tropism for the epidermis, and hair follicle stem cells probably
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20170308

2293

Figure 2. CIB1 levels in patient-derived cells and
healthy skin biopsy specimens. (A) CIB1 mRNA levels
were assessed by RT-qPCR in patient-derived LCLs for kindred A and P12 and in whole blood from P13. Each symbol
represents the mean of three independent measurements
per cell line/donor. Statistical significance (***, P < 0.001)
was assessed in a one-way ANOVA followed by Dunnett’s
multiple comparison test for kindred A. Levels were 47%
lower than the corresponding control mean in P12 and 80%
lower in P13. (B) CIB1 protein was detected in LCLs and
PBMCs with a polyclonal antibody directed against the N
terminus of CIB1. GAPDH and Akt served as loading controls.
Cellular material from kindreds A and B was analyzed three
times. PBMCs from kindred E were analyzed once. (C) CIB1
protein level in skin biopsy specimens from healthy donors
were measured by IHC with a monoclonal antibody directed
against CIB1. An isotype Ig was included as a control. These
results are representative of two experiments, each performed on two patients. *, epidermis; >, hair shaft. Bars:
(top) 100 μm; (middle and bottom) 50 μm. (D) CIB1 protein
was detected in primary keratinocytes from three healthy
controls (ctrl 1–3), kindreds A, C, and D, or in whole-skin
lysates from kindred F. L, lesion. These results are representative of three and one independent experiments, respectively. Asterisk indicates a nonspecific band.

serve as a reservoir for HPV persistence (Orth, 2008). We therefore assessed CIB1 protein levels by immunohistochemistry
(IHC) in skin biopsy specimens from healthy controls. A strong
signal for CIB1 was obtained for the epidermis and hair follicles
(Fig. 2 C). We then assessed CIB1 protein levels in cultured primary keratinocytes from three healthy controls, one heterozygous healthy individual from kindred A (wt/m), and three
patients from kindreds A, C, and D. CIB1 protein levels were high
in control and heterozygous individuals, whereas this protein
was not detected in the patients (Fig. 2 D). We also assessed CIB1
protein levels in whole-skin biopsy lysates from a heterozygous
individual of kindred F (wt/m) and in lysates from both lesional
and nonlesional skin biopsy specimens from his relatives P21
and P23. CIB1 protein was detected in the lysate from the heterozygous individual but not in lesional and nonlesional lysates
from the patients (Fig. 2 D). Thus, CIB1 is clearly abundantly expressed in keratinocytes, the natural host cells of β-HPVs, and the
patients’ skin and cultured keratinocytes display no detectable
CIB1 expression. Finally, we showed that mRNA levels for CIB1,
but also for TMC6 and TMC8, were not increased by type I IFN
treatment in keratinocytes (Fig. S3), consistent with the lack of
β-HPV lesions in patients with inborn errors of type I IFN immunity (Dupuis et al., 2001, 2003; Ciancanelli et al., 2015; Kreins et
al., 2015; Lamborn et al., 2017). Collectively, these findings suggest that AR CIB1 deficiency may underlie EV by disrupting keratinocyte-intrinsic type I IFN-independent immunity to β-HPVs.
Lack of CIB1 expression in EVER1- and EVER2-deficient cells
The clinical and virological phenotypes of EVER1-, EVER2-, and
CIB1-deficient patients are indistinguishable. We therefore analyzed CIB1 levels in LCLs derived from patients with EVER1 or
EVER2 deficiency. Strikingly, individuals carrying inactivating
mutations of either EVER1 (D576*; Ramoz et al., 2002) or EVER2
(D362* [Ramoz et al., 2002] or T150Mfs*3 [Crequer et al., 2013])
had very low levels of CIB1 protein, whereas their heterozygous
de Jong et al.
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relatives had normal CIB1 protein levels (Fig. 3 A). In EVER1- and
EVER2-deficient LCLs, CIB1 mRNA levels were ∼50% lower than
in control LCLs (Fig. 3 B). EVER1 and EVER2 are therefore required for the correct expression of CIB1 protein. We detected
normal EVER1 and EVER2 mRNA levels in CIB1-deficient LCLs
(Fig. 3 B), but a lack of reliable antibodies against EVER proteins
made it impossible for us to assess the levels of the corresponding proteins. We also tested LCLs from patients with T cell defects associated with persistent cutaneous β-HPV infections due
to RHOH or MST1 (encoded by STK4) deficiency (Crequer et al.,
2012a,b). CIB1 levels were normal in cells from these patients
(Fig. 3 A). This dichotomy mirrors the lymphocyte frequency
data (Tables S1 and S4) and suggests that isolated β-HPV–induced
disease in patients with typical EV is caused by a common EVER1/
EVER2- and CIB1-dependent mechanism different from the T
cell–dependent mechanisms of disease in patients with atypical
EV as well as infectious phenotypes including but not limited to
β-HPV–induced lesions.
CIB1, EVER1, and EVER2 form a complex
These findings suggest that CIB1 protein stability might be controlled posttranscriptionally by the EVER1 and EVER2 proteins.
Consistent with this hypothesis, the stable overexpression of
EVER1 in EVER1-deficient LCLs or of EVER2 in EVER2-deficient LCLs rescued CIB1 protein (Fig. 3 C) but not mRNA levels
(Fig. 3 D). As a control, the overproduction of either EVER protein
in CIB1-deficient LCLs did not rescue CIB1 expression (Fig. 3, C
and D). In the absence of robust antibodies against the EVER1
and EVER2 proteins, overexpression was confirmed by assessing mRNA levels (Fig. 3 D). These data suggest that EVER1 and
EVER2 regulate CIB1 expression posttranslationally. We therefore hypothesized that the CIB1, EVER1, and EVER2 proteins
form a multimeric complex that controls CIB1 protein stability.
Reciprocal coimmunoprecipitation experiments in HEK293T
cells showed that CIB1 interacted with both EVER1 and EVER2
Journal of Experimental Medicine
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Figure 3. CIB1 forms a complex with EVER1 and EVER2. (A) CIB1 protein levels in LCLs derived from patients with loss-of-function mutations of EVER1
(D576*) and EVER2 (D362* or T150Mfs*3), and comparison with those in heterozygous carriers, positive controls (ctrl 1 and 2), P4 and P11, and patients with
RHOH and MST1 deficiencies. (B) CIB1, EVER1, and EVER2 mRNA levels were assessed by RT-qPCR in controls (n = 4), CIB1 m/m (P1–P6 and P12), EVER1 m/m,
and EVER2 m/m (n = 3 each) LCLs. Each symbol represents the mean of one cell line measured in three independent experiments. Statistical significance was
assessed by one-way ANOVA followed by Dunnett’s multiple comparison tests relative to healthy controls. (C) CIB1 protein levels in LCLs derived from patients
with loss-of-function mutations of EVER1 (D576*), EVER2 (T150Mfs*3), and a healthy control after reconstitution with WT EVER1 or EVER2 by retroviral transduction and stable selection. Asterisk indicates a nonspecific band. (D) CIB1, EVER1, and EVER2 mRNA levels were measured by RT-qPCR in LCLs derived from
patients with loss-of-function mutations of EVER1 (D576*), EVER2 (T150Mfs*3), or CIB1 and a healthy control after reconstitution with WT EVER1 or EVER2 by
retroviral transduction and stable selection. The data were first normalized against RNaseP as a housekeeping gene and then against an appropriate untransduced parental cell line by the ΔΔCt method. Statistical significance was assessed by one-way ANOVA followed by Dunnett’s multiple comparison test relative
to the corresponding untransduced control. (B and D) ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (E) HEK293T cells were transfected with plasmids
encoding CIB1-HA, FLAG-EVER1, and FLAG-EVER2 either separately or together; 24 h after transfection, samples were subjected to immunoprecipitation with
FLAG (Fl)- or HA-specific antibodies (+). Samples incubated with nonspecific IgG served as specificity controls. Western blots were performed to detect coimmunoprecipitated CIB1-HA and FLAG-EVER1 or FLAG-EVER2. The immunoprecipitation of EVER1/2 and CIB1 was confirmed by reincubation with antibodies
specific for FLAG and HA, respectively. The presence of all proteins was checked by Western blotting of an input sample taken before immunoprecipitation.
GAPDH served as a loading control. vec, vector. (F) Healthy control keratinocytes were transfected with plasmids encoding CIB1-HA, FLAG-EVER1, and FLAGEVER2 either alone or in combination; 24 h after transfection, cells were subjected to immunofluorescence imaging with Alexa Fluor 568–HA and Alexa Fluor
488–FLAG antibody combinations. DAPI was used for counterstaining. Colocalization was assessed by calculating Pearson’s correlation coefficient with Imaris
software. Bar, 13 µm. The results shown are representative of three independent experiments.

(Fig. 3 E). Subsequent immunofluorescence analysis in primary
keratinocytes indicated that overproduced CIB1 was mostly localized in the nucleus. However, on coexpression with EVER1 or
EVER2, CIB1 was localized in perinuclear and cytoplasmic weblike structures that strongly colocalized with EVER1 or EVER2 as
demonstrated quantitatively by the calculation of Pearson’s corde Jong et al.
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relation coefficient (Fig. 3 F). Furthermore, mass spectrometry
on CIB1 immunopurified after its ectopic expression in HEK293T
cells identified endogenous EVER1 as the highest-ranked interactor of CIB1 (Fig. S4 A). EVER2 was not detected probably because
its mRNA was barely detectable in HEK293T cells at levels lower
than those of EVER1 by a factor of at least 60 (Fig. S4, B–D). ColJournal of Experimental Medicine
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lectively, these data strongly suggest that a multimeric complex
of CIB1 and EVER1/EVER2 proteins is required for CIB1 protein
stability. They connect CIB1 directly with the previously identified EV-causing proteins EVER1 and EVER2.
CIB1 does not affect intracellular free zinc and NF-κB signaling
The interaction between CIB1 and EVER1/2 led us to investigate
the contribution of CIB1 to the known functions of EVER1 and
EVER2 (Lazarczyk et al., 2008; Vuillier et al., 2014). EVER1 and
EVER2 have been reported to control intracellular zinc homeostasis by binding to the zinc transporter ZnT1, increasing its activity to import zinc into the ER storage compartment, thereby
controlling free intracellular zinc levels (Lazarczyk et al., 2008).
We overproduced EVER1 and EVER2 in HEK293T cells; both proteins repressed the basal and zinc-induced transcription of a
GFP reporter construct via the metal-response element (MRE;
Günther et al., 2012; Fig. 4 A), consistent with previous findings
(Lazarczyk et al., 2008). However, CIB1 overexpression had no
effect on MRE activity, and no additional effect was observed
when CIB1 was coexpressed with EVER1 or EVER2 (Fig. 4 A),
consistent with the lack of colocalization of CIB1 and ZnT1 (Fig.
S4 E). Moreover, our findings confirmed the interaction between the overproduced EVER1/2 and ZnT1 proteins (Lazarczyk
et al., 2008), but we detected no interaction between CIB1 and
ZnT1 in the same conditions (not depicted). At odds with this
previous study (Lazarczyk et al., 2012), the absolute amounts
of free zinc, determined with the fluorescent zinc reporter Fluozin-3, were unaffected in LCLs from patients with EVER1 or
EVER2 deficiency (Fig. 4 B). Consistent with these findings, P1–
P5, P7, and P12 also had normal free zinc levels in LCLs, and P14
had normal amounts of zinc in primary keratinocytes (Fig. 4 B).
Furthermore, all cell lines had zinc flux kinetics in the control
range (Fig. 4 C). No statistically significant effect of genotype
was detected in a two-way repeated-measures ANOVA. Thus,
the overexpression of EVER1 and EVER2 modulated zinc-dependent transcription, whereas that of CIB1 did not, and endogenous EVER1/2 and CIB1 deficiencies had no overt effect on
zinc homeostasis, implying that the mechanism underlying EV
is zinc independent. Finally, an analysis of TNFα-dependent
canonical and noncanonical NF-κB activation upon overexpression of EVER1, EVER2, CIB1, or a combination of these genes in
HEK293T cells revealed no differences relative to an empty vector–transfected control (Fig. 4 D), at odds with previous studies
(Gaud et al., 2013; Vuillier et al., 2014). Moreover, CIB1-deficient
keratinocytes from P5 and P14 displayed normal NF-κB activation in response to TNFα, as shown by assessments of IκBα phosphorylation (Fig. 4 E). This finding is consistent with the fact
that none of the many known inborn errors of NF-κB underlie
skin lesions caused by β-HPVs (Zhang et al., 2017). Thus, studies
of the known functions of EVER1 and EVER2 identified no phenotype common to EVER1-, EVER2-, and CIB1-deficient cells. As
the three genetic deficiencies are AR with complete penetrance
and underlie strict virological and clinical phenocopies and the
three proteins are required for the stability of an oligomeric
complex, these findings suggest that the major mechanism of
EV pathogenesis is probably unrelated to zinc metabolism and
NF-κB activation.
de Jong et al.
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CIB1 deficiency does not affect keratinocyte
adhesion and migration
We then focused our attention on the known functions of CIB1.
None of the four phenotypes of CIB1-deficient mice were seen in
our patients, who had no cardiac, vascular, hemostasis, or fertility abnormalities (Yuan et al., 2006; Zayed et al., 2007; Naik et al.,
2009; Heineke et al., 2010). CIB1 has not been studied in human
or mouse keratinocytes. However, it has been reported to localize to focal adhesions and to modulate cell migration (Leisner et
al., 2016). The keratinocytes of P5 contained normal levels of the
focal adhesion proteins vinculin and focal adhesion kinase (FAK)
and displayed normal FAK activation, as shown by Western blot
analyses of phosphorylation (pFAK), relative to two unrelated
healthy controls and a heterozygous family member (Fig. 5 A).
We assessed the formation of focal adhesions by performing immunofluorescence staining for vinculin- and pFAK-positive focal
adhesion structures in CIB1-deficient keratinocytes. Automated
surface detection and quantification showed these adhesions
to be of normal size, fluorescence intensity, and morphology,
similar to those of healthy controls and heterozygous relatives
(Fig. 5, B and C). Consistent with these results, CIB1 deficiency
had no detectable effect on the ability of keratinocytes to migrate in scratch-wounding assays, although the results obtained
were at the lower end of the control range (Fig. 5, D, E, and F). Finally, we compared the transcriptomes of WT keratinocytes and
CIB1-deficient keratinocytes and of CIB1-deficient keratinocytes
and GST- or WT-CIB1–transduced CIB1-deficient keratinocytes.
We identified only 40 genes displaying at least a twofold downor up-regulation. These genes included CIB1 but not EVER1 or
EVER2, consistent with our quantitative PCR (qPCR) data. No
enrichment in a specific pathway was detected among these
genes (Table S6). Thus, the lack of CIB1 caused no overt cellular phenotype related or unrelated to the known functions of
EVER1, EVER2, or CIB1 in LCLs or primary keratinocytes. These
data are consistent with the very narrow clinical phenotype of
EV patients, who are highly and selectively vulnerable to β-HPV
but otherwise healthy. However, they provide no insight into the
potential mechanism underlying β-HPV–driven lesions as even
keratinocytes displayed no detectable phenotype.
CIB1, EVER1, and EVER2 interact with the HPV E5
and E8 proteins
These results suggest that CIB1-deficient keratinocytes may display their EV-causing phenotype only in the presence of β-HPV
infection. Antiviral restriction factors are commonly targeted
and antagonized by viral proteins (Duggal and Emerman, 2012).
The specific feature of the β-HPVs underlying EV lesions is their
lack of the E5 and E8 open reading frames (ORFs), rendering
them defective in healthy individuals (Orth, 2006). The E8 ORFs
from μ-HPV1, γ-HPV4, and κ-CRPV are structurally related to the
E5 ORF, and the corresponding proteins function as growth-promoting factors in E5-deficient κ-papillomaviruses (Orth, 2008).
Indeed, it has been shown that CRPV-E8 is crucial in vivo (Hu et
al., 2002; Nonnenmacher et al., 2006). E5 and E8 are both hydrophobic transmembrane proteins with weak transforming
activity in vitro (Nonnenmacher et al., 2006). As EV patients are
prone only to cutaneous disease caused by β-HPVs, we hypothJournal of Experimental Medicine
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Figure 4. Analysis of zinc signaling/levels and NF-kB activation in the presence and absence of CIB1. (A) HEK293T cells were transfected with plasmids
encoding CIB1, EVER1, and EVER2 either alone or in combination and with a 4×MRE-dependent EGFP reporter construct. After 24 h, cells were stimulated
overnight with PMA/ionomycin (10 ng/ml and 50 ng/ml, respectively) or zinc sulfate (ZnSO4; 100 µM). The next day, cells were stained with 1 µg/ml DAPI to
exclude dead cells, and GFP fluorescence was determined with an LSRII flow cytometer. The RRR with the value for vector-transfected cells was set at 100%.
Statistical significance was assessed by one-way ANOVA followed by Dunnett’s multiple comparison test relative to the appropriate vector-transfected control
(ns, P > 0.05; *, P < 0.05; ***, P < 0.001; n = 3). (B) Flow cytometric quantification of absolute amounts of labile zinc in LCLs derived from healthy controls,
EVER1-, EVER2-, or CIB1-deficient patients, or in keratinocytes from P14 with 1 µM FluoZin-3 as described by Haase et al. (2006). Statistical significance was
assessed by one-way ANOVA followed by Dunnett’s multiple comparison test relative to the healthy controls (n = 3). (C) Kinetics of zinc flux in LCLs derived from
healthy controls and EVER1-, EVER2-, or CIB1-deficient patients. Cells were loaded with 1 µM FluoZin-3 for 30 min. Fluorimetric measurement were performed
on a Victor microplate reader. Baseline fluorescence was recorded every minute for 10 min. Cells were then loaded with 100 µM ZnSO4 and recorded for 15
min. The specificity of the zinc signal was confirmed by adding the calcium-specific chelator BAPTA before the quenching of the signal with the zinc-specific
chelator TPEN and recording for 20 min. No significant effect of genotype was detected in two-way repeat-measures ANOVA (n = 3). (D) HEK293T cells were
transfected with plasmids encoding CIB1-FLAG, FLAG-EVER1, and EVER2 either alone or in combination. Cells were stimulated with 50 ng/ml TNFα 6 h after
transfection, incubated overnight, and then harvested and processed for Western blotting. Membranes were probed for the canonical NF-κB component (p)
IκBa and the noncanonical NF-κB component p100/p52. Expression of the constructs used for transfection was verified by incubation with a FLAG-specific
antibody. GAPDH served as a loading control (n = 3). (E) Primary keratinocytes from unrelated donors (controls 1 and 2), a healthy family member from kindred
A1 carrying the mutation in a heterozygous state (A1.viii.2), and one patient each from kindreds A1 and C were stimulated with 10 ng/ml TNFα for 5, 10, or 20
min and then harvested and processed for Western blotting. Membranes were probed for the canonical NF-κB component (p)IκBa. CIB1 levels were assessed
with a polyclonal antibody. GAPDH served as a loading control. vec, empty vector (n = 3).

esized that the EVER1–EVER2–CIB1 complex interacts with E8
and E5 produced early in infection. We considered γ-HPV4 E8
and κ-CRPV E8, all β-HPV5 early-expressed ORFs (E1, E2, E6, and
E7), and as controls, all α-HPV16 early-expressed ORFs (E1, E2,
E5α, E6, and E7). We assessed the ability of the corresponding
proteins to interact with CIB1 in the human keratinocyte cell line
HaCaT in Duolink proximity-ligation assays (PLAs) by fluorescence microscopy followed by the automated surface detection
and quantification of total fluorescence intensity. This approach
can be used to detect proteins lying in close proximity and therefore likely to form a complex. This approach revealed that CIB1
was indeed targeted by HPV4 E8, CRPV E8, and HPV16 E5 but
also by HPV5 E1 and HPV16 E2 and not by any of the other six
E proteins from these two HPVs (Fig. 6 A). We then confirmed
these interactions by coimmunoprecipitation/immunoblotting
in HaCaT cells (Fig. 6 B). Collectively, these experiments showed
that CIB1 interacts with both the γ-HPV4 E8 and α-HPV16 E5
proteins. These findings are consistent with a previous study
de Jong et al.
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showing that EVER proteins interact with HPV16 E5 (Lazarczyk
et al., 2008). The interaction between β-HPV5 E1 and HPV16 E2
and CIB1 but not between HPV5-E2 and CIB1 suggests that the
CIB1–EVER1–EVER2 complex or at least CIB1 might be involved
against other cutaneous or mucosal HPVs in patients without EV.
All these observations provide a plausible mechanism of disease
in patients with EV. β-HPVs lacking the E5 and E8 ORFs cannot
overcome the CIB1–EVER1–EVER2 complex, which probably operates as a restriction factor in keratinocytes (Fig. 7). Conversely,
in patients lacking EVER1, EVER2, or CIB1, the lack of this restriction factor allows β-HPV–driven lesions to develop.

Discussion

We report AR complete CIB1 deficiency as a new genetic cause
of EV. We identified two frameshift insertions (I156Dfs*5 and
A184Lfs*70), one frameshift deletion (K83Rfs*4 in two kindreds),
one nonsense mutation (R72*), and one splice mutation (c.52Journal of Experimental Medicine
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Figure 5. Focal adhesion formation and scratch
wounding in CIB1-deficient keratinocytes. (A) Primary keratinocytes from two donors, a healthy member
of kindred A (A1.viii.2; CIB1 wt/m), and P5 were allowed
to adhere to fibronectin-coated plates (10 µg/ml) for the
times indicated and were then harvested and processed
for Western blotting. The membranes were probed for
the focal adhesion (FA) components vinculin and (p)FAK.
GAPDH served as a loading control. (B and C) Primary
keratinocytes from two donors, a healthy member of
kindred A (A1.viii.2), and P5 were allowed to adhere to
fibronectin-coated coverslips (10 µg/ml) for 24 h. Cells
were fixed and stained with vinculin- and pFAK-specific
antibodies. Z stacks were acquired with a confocal microscope. (B) Representative image for automated surface
detection for control 1. Bar, 40 µm. (C) The volume (size),
fluorescence intensity, and morphology of the vinculin- and pFAK-positive structures were automatically
determined with Imaris. Values were normalized against
the total number of surfaces detected. Statistical significance was assessed in one-way ANOVA followed by
Dunnett’s multiple comparison test relative to control 1.
No significant differences were detected for any of the
parameters tested (P > 0.05). (D–F) Primary keratinocytes from two donors, a healthy member of kindred A
(A1.viii.2; CIB1 wt/m), and P5 were allowed to adhere to
fibronectin-coated plates (1 µg/ml) overnight. Scratch
wounds were created with a pipette tip, and wound closure was monitored by live-cell microscopy every 20 min
for 16 h. Bar, 283 µm. Wound closure was then quantified automatically with the MiToBo plugin in ImageJ with
measurement of the cell-free area normalized against
the starting point (set to 100%; D and E). Statistical significance was assessed by two-way repeated-measures
ANOVA. Differences between controls 1 and 2, CIB1
wt/m, and P5 were statistically significant. Differences
between control 2, CIB1 wt/m, and P5 were not significant. (F) For confirmation of the accuracy of the results
obtained with the plugin, the total cell-free area at the
start and end points was determined manually. The data
shown are the means of two (controls 1 and 2) or three
(CIB1 wt/m and P5) independent experiments with at
least six data points acquired per set. Statistical significance was assessed by one-way ANOVA followed by
Dunnett’s multiple comparison test relative to controls
1 or 2. (ns, P > 0.05; ***, P < 0.001).

2A>G) in 24 patients from six families from five ethnically and
ecologically diverse countries: Colombia, France, Iran, Switzerland, and Togo. None of the heterozygous relatives of the patients
show any clinical signs of EV, whereas all homozygous individuals suffer from EV. The familial segregation of the mutant CIB1
alleles is consistent with an AR trait displaying complete clinical
penetrance, but CIB1 deficiency is associated with somewhat
variable expressivity, as also reported for the deficiencies in families with EVER1 and EVER2 mutations (Orth, 2006, 2008; Burger
and Itin, 2014). For example, in kindred A, the phenotype ranged
from very mild manifestations in P1 and P4 to more aggressive
disease with early cancer development in siblings P2, P3, and P5.
Nevertheless, in all patients, CIB1 deficiency led to the development of EV from the age of 23 yr onward (the age at which clinical penetrance can be said to be complete in this cohort). Finally,
none of these patients suffered from any other unusually severe
infection, like patients with EVER1 or EVER2 deficiencies and
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unlike those with atypical EV and T cell deficits. AR CIB1, EVER1,
and EVER2 deficiencies are therefore indistinguishable clinical
and virological phenocopies, consistent with a typical form of EV.
CIB1 has been reported to have pleiotropic functions both in
vitro in cell culture models and in vivo in knockout mice (Leisner
et al., 2016). Mice lacking Cib1 have vascular, cardiac, and hemorrhagic phenotypes, and their males are sterile (Yuan et al., 2006;
Naik et al., 2009). By contrast, none of these phenotypes were
observed in patients, indicating that CIB1 is not essential for these
functions in humans. Low CIB1 mRNA levels are unlikely to be
causally associated with oligoasthenozoospermia-related sterility (Sun et al., 2014) as a complete absence of the CIB1 protein
had no effect on male fertility in our cohort. We know that this
observation is robust because we have diagnosed 24 CIB1-deficient patients from six kindreds originating from very diverse
ethnicities. Our findings suggest that the only nonredundant
function of CIB1 in humans in vivo is the control of β-HPVs in
Journal of Experimental Medicine
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Figure 6. PLA and coimmunoprecipitation in HaCaT. (A) HaCaT cells were transfected with plasmids encoding FLAG-HPV5 E1, E2, E6, and E7, FLAG-HPV16
E1, E2, E5, E6, and E7, FLAG-HPV4 E8, FLAG–CRPV E8, and CIB1-HA alone or in combination. The day after transfection, samples were plated on microscopy
slides, allowed to adhere, fixed in acetone, permeabilized, and subjected to Duolink PLAs with rabbit-HA– and mouse-FLAG–specific antibodies. Z stacks were
acquired with a widefield microscope, and PLA-positive sites (defined as structures >0.35 µM2) were scored with Imaris software for 15–50 cells per condition.
These pooled results were obtained in two independent experiments. The orange bars indicate the mean. (B) HaCaT cells were transfected with plasmids
encoding CIB1-HA and the FLAG-tagged HPV E ORFs scoring positive in the PLA in A. 1 d after transfection, samples were subjected to immunoprecipitation
(IP) with FLAG-specific antibodies. Western blots were performed to detect coimmunoprecipitated HPV5 E1, HPV16 E2, E5, HPV4 E8, and CRPV E8. The immunoprecipitation of CIB1 was confirmed by reincubation with a FLAG-specific antibody. The presence of all proteins was checked by Western blotting analysis
on an input sample taken before immunoprecipitation. GAPDH served as a loading control (n = 3). vec, vector.

keratinocytes. Cib1-deficient mice have not been challenged with
infectious agents including skin-tropic viruses. The only known
mouse-tropic papillomavirus, Mus musculus papillomavirus
type 1 (MuPV1; Ingle et al., 2011), does not belong to the β genus
(Joh et al., 2011).
Our identification of AR CIB1 deficiency establishes a third
genetic etiology of typical EV after AR EVER1 and EVER2 defi-

Figure 7. Mechanism underlying EV. (A) In the general population, the
CIB1–EVER1–EVER2 complex restricts the transcription of minichromosome
of β-HPV, leading to the absence of clinical manifestation. The proteins E5 and
E8 expressed by the other cutaneous HPVs (α2-, α4-, γ-, and μ-HPVs) are able
to antagonize the CIB1–EVER1–EVER2 complex. However, additional restriction factors are probably contributing to the absence of HPV lesions in the vast
majority of people. (B) In EV patients, the lack of CIB1–EVER1–EVER2 permits
the transcription of β-HPV minichromosome, which leads to the development of EV lesions on the skin. However, the probable presence of additional
restriction factors against cutaneous HPVs other than β-HPVs accounts for
their normal control, which does not differ from the general population.
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ciencies. Six different homozygous and two compound heterozygous mutations of TCM6 have been described in 14 patients
from eight kindreds (Ramoz et al., 2002; Tate et al., 2004; Zuo
et al., 2006; Aochi et al., 2007; Gober et al., 2007; Youssefian et
al., 2018), and 11 homozygous mutations of TCM8 have been described in 17 patients from 11 kindreds (Ramoz et al., 2002; Sun
et al., 2005; Berthelot et al., 2007; Rady et al., 2007; Landini et al.,
2012; Burger and Itin, 2014; Miyauchi et al., 2016; Imahorn et al.,
2017; de Jong et al., 2018; Youssefian et al., 2018). All these mutations are loss of function. The identification of five homozygous
loss-of-function alleles of CIB1 markedly increases the number
of EV cases for which explanations have been found at the genetic and molecular levels. Moreover, we identified a molecular
connection between CIB1, EVER1, and EVER2 as shown by the
very low levels of CIB1 proteins in cells from patients with EVER1
or EVER2 deficiency. This is reminiscent of the interaction between TMC1, TMC2, and CIB2 in inner-ear hair cells, which is
required for normal sensory transduction (Giese et al., 2017). Our
observation provides a unifying cellular phenotype common to
all known genetic etiologies of typical EV. CIB1 protein profiling
could therefore be used as a simple laboratory test for screening
patients with suspected EV, making it possible to target sequencing efforts on CIB1, TMC6, and TMC8 in patients with low levels
of CIB1 protein.
The clinical characteristics of EVER1- and EVER2-deficient
patients (EV in the absence of other clinical manifestations;
Orth, 2006, 2008; Burger and Itin, 2014) and of the patients
with CIB1 deficiency described in this study are identical and
markedly different from those of patients with atypical EV due
to CD4+ T cell lymphopenia caused by RHOH, MST1 (encoded by
STK4), CORO1A, ARTEMIS (encoded by DCLRE1C), DOCK8, RAS
GRP1, LCK, and TPP2 deficiencies. In such patients, persistent
β-HPV–induced lesions occur in the context of a much broader
infectious, autoimmune, and tumoral phenotype (Crequer et al.,
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2012a,b; Sanal et al., 2012; Stray-Pedersen et al., 2014; Stepensky
et al., 2015; Li et al., 2016; Tahiat et al., 2016; Liu et al., 2017; Platt
et al., 2017). Consistent with this observation, the CIB1-deficient
patients tested in this study had no detectable T-lymphocyte defects in terms of either cell numbers or functions. The clinical
and immunological dichotomy between typical and atypical EV
is reflected at the cellular level by the profile of CIB1 expression
profile, with very low levels of CIB1 in patients with EVER1 and
EVER2 deficiencies but not in patients with RHOH and MST1 deficiencies. These findings support the notion that patients with
typical EV have intact adaptive immunity and suffer from an inborn error of cell-intrinsic immunity, resulting in an inability to
control β-HPV–driven keratinocyte proliferation.
Inherited CIB1 deficiency is not associated with any detectable, constitutive phenotype in keratinocytes in terms of the
transcriptome, cell growth, migration, or adhesion. CIB1 deficiency also has no impact on zinc homeostasis and NF-κB activation, suggesting that EVER proteins have other functions shared
by CIB1 that are involved in the pathogenesis of EV. We reveal in
this study a phenotype of CIB1, EVER1, and EVER2 deficiencies
that is conditional on infection with β-HPVs. Our findings suggest
that the CIB1–EVER1–EVER2 complex interacts in vivo with both
cutaneous γ-HPV4 E8 and κ-CRPV E8 as well as with α-HPV16
E5. In this light, it is plausible that β-HPVs that lack both the E5
and E8 ORFs cannot overcome the CIB1–EVER1–EVER2 complex,
unlike α-, γ-, and μ-HPVs and CRPV, which cause disease more
widely in the general population (Fig. 7). Both E5 and E8 are hydrophobic and transmembrane proteins with weak transforming activity in vitro but potent growth-promoting activity in vivo
(Hu et al., 2002; García-Vallvé et al., 2005; Nonnenmacher et al.,
2006; Maufort et al., 2007; Orth, 2008; Wechsler et al., 2018).
Conversely, the E5 and E8 proteins target and antagonize the
CIB1–EVER1–EVER2 complex, thereby contributing to virulence
to α-, γ-, and μ-HPVs, which cause cutaneous warts in the general
population. By contrast, β-HPVs are capable of causing disease
only in EV patients lacking the CIB1–EVER1–EVER2 complex. The
interaction of β-HPV5 E1 and α-HPV16 E2 with CIB1 is probably
not sufficient to antagonize the EVER–CIB1 complex, yet it suggests that this complex might be involved in the pathogenesis of
the disease caused by various HPVs. However, EV patients are
apparently not more prone to develop common HPV warts, suggesting that immunity against cutaneous non–β-HPVs relies on
mechanisms other than the CIB1–EVER1–EVER2 complex (Fig. 7).
We have established that EV is caused by mutations of the genes
encoding the proteins of the CIB1–EVER1–EVER2 complex, which
acts as a restriction factor for HPVs in keratinocytes through
interaction with two viral E proteins, E8 and E5, which are absent from β-HPVs.
The CIB1–EVER1–EVER2 complex fulfills the five criteria commonly used to define restriction factors active against viruses
(Duggal and Emerman, 2012). First, the lack of CIB1, EVER1,
or EVER2 is clinically associated with EV, lesions of which are
caused by β-HPVs. Second, patients lacking the CIB1–EVER1–
EVER2 complex display no other detectable cellular or clinical
phenotype. Third, the CIB1–EVER1–EVER2 complex operates in
keratinocytes, the host cells of β-HPVs. Fourth, E5 and E8 are
viral virulence genes expressed by cutaneous α-, γ-, and μ-HPVs
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but not β-HPVs, and the products of these genes target the CIB1–
EVER1–EVER2 complex. Fifth, human CIB1 belongs to a multigene family with four members. We do not provide experimental
evidence for the control of β-HPVs by the CIB1–EVER1–EVER2
complex in keratinocytes in vitro as this work would have gone
well beyond the scope of this study given the technical difficulties involved. Nevertheless, we provide the first in vivo evidence
of a restriction factor operating in humans. Other restriction factors in humans have been validated in vitro or in animal models
(Kluge et al., 2015; Subramanian et al., 2018). The pathogenesis
of the β-HPV–driven skin lesions characteristic of EV in patients
with AR CIB1, EVER1, or EVER2 deficiency involves the disruption of skin-restricted, cell-autonomous, nonhematopoietic,
keratinocyte-intrinsic, IFN-independent restriction factor (the
CIB1–EVER1–EVER2 complex)–mediated immunity against a
specific set of defective viruses (β-HPVs, which lack E5 and E8).

Materials and methods

Patients and case studies
The clinical characteristics of all patients are summarized in
Table 1. The experiments involving human subjects were conducted in accordance with local, national, and international regulations and were approved by the French Ethics Committee, the
French National Agency for the Safety of Medicines and Health
Products, and the French Ministry of Research (protocol C10-13)
as well as The Rockefeller University Institutional Review Board
(protocol JCA-0700). Informed consent was obtained from all patients or their family members included in this study.
Kindred A (branches A1 and A2; P1–11)
Branches A1 and A2 of kindred A originate from the same region
of Colombia, and affected individuals in these two branches of
the family are homozygous for the same 3-Mb haplotype encompassing a disease-linked interval on chromosome 15 that harbors
CIB1, consistent with a common ancestor for these two families.
Kindred A, branch A1 (Figs. 1 A and S1; Tables 1, S1 A, S2, S3, S4,
and S5). P1–P5 were born to second-degree cousins (Fig. 1 A). The
consanguinity of this family was confirmed by the high inbreeding coefficient determined by SNP 6.0 array analysis (Table S5).
Neither of the parents displayed any signs of cutaneous HPV infection or EV. The clinical characteristics of P2, P3, and P5 have been
reported previously (Rueda, 1993). All five patients mounted normal antibody responses to various DNA viruses (HSV-1/2, varicella
zoster virus, CMV, EBV, and hepatitis B) and RNA viruses (hepatitis
A, hepatitis C, measles, rubella, and mumps) as shown by comparison with 12 healthy family members (Table S3). Furthermore,
P1–P4 were extensively phenotyped for skin-homing total CD3+,
CD4+, and CD8+ T cell subsets (CLA+, CLA+CCR4+, CLA+CCR10+, and
CCR10+), and no alterations were detected relative to five unrelated healthy donors and nine healthy family members (Table S4).
P1 (A1.viii.4; Fig. 1 A) has a very mild EV phenotype. She first
developed persistent flat warts on the back of her hands at the
age of 12 yr. At the age of 15 yr, she developed warts on her face.
She is not currently followed by a dermatologist.
P2 (A1.viii.7; Fig. 1 A) presented with brownish macules on his
hands at the age of 6 yr. He was formally diagnosed at the age of
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13 yr. The hyperpigmented lesions progressively spread, forming
flat warts on his breast, neck, forehead, legs, and feet (Fig. S1 A).
The lesions on his forehead were hypochromic, and the lesions
on his trunk were pityriasis versicolor–like. He developed an
invasive ulcerating SCC on the right-hand side of his forehead,
which was surgically removed. He was treated by cryotherapy
and with topical 5-fluorouracil. Restriction enzyme analysis and
Southern blot hybridization showed that P2 was carrying HPV8,
HPV17, and HPV20. P2 also suffered from chronic hepatitis C
virus–induced hepatitis and died from hepatic carcinoma at the
age of 47 yr. This patient was described as case 11 by Rueda (1993).
P3 (A1.viii.10; Fig. 1 A) presented with flat warts at the age of 7
yr. She was formally diagnosed at the age of 13 yr. She displayed
reddish and hyperpigmented flat warts on her forehead, trunk,
arms, hands, and legs. She developed three SCCs on the forehead and lips after the age of 13 yr. Restriction enzyme analysis
and Southern blot hybridization showed that P3 carried HPV8
and HPV20. This patient was reported as case 12 in a previous
study (Rueda, 1993). She displays no immunological abnormalities of T cells, B cells, NK cells, or monocytes (Table S1 A), and
her T cell proliferation after anti-CD3 antibody stimulation was
normal (Table S2).
P4 (A1.viii.12; Fig. 1 A) presented with flat warts at the age of 7
yr and was formally diagnosed at the age of 22 yr. Her lesions are
located on the head and trunk. She has not yet developed SCCs.
She was shown to be HPV8 positive by restriction enzyme analysis and Southern blot hybridization.
P5 (A1.viii.15; Fig. 1 A) presented with flat warts on his forehead at the age of 5 yr. The lesions spread to his hands, trunk, and
upper legs over time. He was formally diagnosed with EV at the
age of 7 yr. He developed an SCC on his forehead at the age of 31
yr, which was surgically removed. He is currently being treated
by cryotherapy and protection against sun exposure. Restriction
enzyme and Southern blot analyses showed that he carried HPV8
and HPV20. This patient was described as case 13 in a previous
study (Rueda, 1993). He displays no immunological abnormalities
of T cells, B cells, NK cells, or monocytes (Table S1 A), and his T
cell proliferation in response to anti-CD3 antibody stimulation
was normal (Table S2).
P6 (A1.iv.13; Fig. 1 A) presented with diffuse flat warts at the
age of 1 yr. He was formally diagnosed with EV at the age of 29
yr. He had numerous lesions over his entire body except for the
scalp, palms, soles of his feet, and mucous membranes. The backs
of his hands and his arms and legs were particularly severely affected. Erythematous squamous and pigmented lesions evolved
to Bowen’s disease and recurrent invasive SCC after the age of
15 yr. Histologically, these lesions consisted of large cells with
an extensive clear cytoplasm and vacuolar nuclei in both the
stratum spinosum and granular layer of the epidermis, a feature
pathognomonic for EV. In semithin sections, inclusion bodies,
also typical of EV, were identified. This patient died at the age of
47 yr due to multiple aggressive SCCs. He was reported as case
6 in a previous study (Rueda, 1993). Unfortunately, this patient
died >35 yr ago, precluding genetic analysis.
P7 (A1.viii.30; Fig. 1 A), belonging to another branch of kindred A1, displayed consanguinity because one of his parents was
the offspring of second cousins. Familial consanguinity was conde Jong et al.
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firmed by a high inbreeding coefficient determined by SNP 6.0
array analysis (Table S5). From the age of 5 yr, P7 presented eruptions of pityriasis versicolor–like and scaly erythematous lesions
on the face and neck, which spread as flat warts to his trunk,
forearms, legs, and the backs of his hands. He developed infiltrative lesions, histologically defined as Bowen’s disease, at the
left medial canthus and on the nose. P7 was treated surgically for
Bowen’s disease and then topically with retinoic acid and 5-fluoruracil. P7 tested positive for HPV5, HPV17, and HPV36 by restriction enzyme analysis and Southern blot hybridization. This
patient was described as case 7 in a previous study (Rueda, 1993).
Kindred A, branch A2 (Fig. 1 A and Tables 1 and S5). P8–P11 were
born to healthy parents. Familial consanguinity was suspected
and confirmed on the basis of a high inbreeding coefficient in
P11 as determined by 250K array analysis (Table S5). The clinical
characteristics of P8–P11 have been described previously (Rueda
and Rodriguez, 1976; Rueda, 1993). All patients had normal karyotypes and serum Ig levels.
P8 (A2.ii.1; Fig. 1 A) first presented with EV at the age of 1 yr,
but she was not formally diagnosed until the age of 59 yr. She
presented with flat warts on her head, trunk, and extremities.
She developed SCC on her forehead at the age of 47 yr. Restriction
enzyme analysis and Southern blot hybridization demonstrated
the presence of HPV5, HPV8, HPV20, and HPV24 in this patient.
She died at the age of 78 yr. This patient was described as case
1 in previous studies (Rueda and Rodriguez, 1976; Rueda, 1993).
HPV5 was cloned from benign and malignant lesions from P8 and
characterized (Deau et al., 1993). HPV20 was originally cloned
from a benign lesion from P8 (Kremsdorf et al., 1984).
P9 (A2.ii.10; Fig. 1 A) first presented with EV at the age of 5
yr, but she was not formally diagnosed until the age of 40 yr. She
presented with flat warts on her head, trunk, and extremities.
SCC development has never been reported for this patient. Restriction enzyme analysis and Southern blot hybridization confirmed that this patient was carrying HPV8. This patient was
described as case 2 in previous studies (Rueda and Rodriguez,
1976; Rueda, 1993). HPV5 from P9 was cloned and characterized
as case B by Deau et al. (1991) and case 4 by Deau et al. (1993).
P10 (A2.ii.12; Fig. 1 A) first presented with EV at the age of
1 yr. He was not formally diagnosed until the age of 40 yr. He
presented with flat warts on his head, trunk, and extremities. He
developed SCC on his forehead and lips after the age of 26 yr, and
he died at the age of 48 yr. This patient was described as case 3 in
two previous studies (Rueda and Rodriguez, 1976; Rueda, 1993).
P11 (A2.ii.13) first presented with EV at the age of 3 yr but was
not formally diagnosed until the age of 36 yr. He presented with
flat warts on his head, trunk, and extremities. He developed invasive SCC and basal cell carcinoma on his forehead after the age
of 27 yr. He died at the age of 48 yr. Restriction enzyme analysis
and Southern blot hybridization confirmed that this patient was
carrying HPV5, HPV8, and HPV20. He was described as case 4 in
two previous studies (Rueda and Rodriguez, 1976; Rueda, 1993).
Kindred B (P12; Fig. 1 A and Tables 1 and S5)
P12 (B.ii.2; Fig. 1 A) was previously described in a case study
(Kienzler et al., 1979). He was born to French parents in 1933. Potential parental consanguinity was investigated by calculating an
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inbreeding coefficient with FSuite software (Gazal et al., 2014).
This analysis indicated that his parents were first cousins (Table
S5). P12 presented with recurrent polymorphic skin lesions typical of EV from the age of 23 yr onwards. He developed several
SCCs on the forehead, cheek, and ear ∼20 yr after the onset of
the disease. The viral etiology of his disease was confirmed by
the identification of HPV8 by restriction enzyme analysis and
by Southern blotting. P12 had normal levels of Ig, complement
components, and cellular immunity as shown by measurements
of dinitrochlorobenzene sensitization, rosette assays, leukocyte
migration, and lymphocyte proliferation. P12 died from natural
causes at the age of 72 yr.
Kindred C (P13 and P14; Fig. 1 A and Tables 1 and S5)
P13 (C.ii.1; Fig. 1 A) and P14 (C.ii.2; Fig. 1 A) were among the first
EV patients documented by Lutz, who was the first to describe
this disease and followed these two sisters from 1929/1930 onwards (Lutz, 1946). Both patients were also described in a more
recent study (Arnold et al., 2011). They were born to Swiss parents who were shown to be consanguineous by inbreeding coefficient analyses (Table S5). P13 was born in 1912. She developed flat
wart-like lesions on her neck, face, and on the backs of her hands
in childhood, and these warts persisted throughout her life. After
the age of 35 yr, she developed several actinic keratoses and SCC.
She died of locally invasive SCC with regional lymph node metastasis at the age of 71 yr. P14 was born in 1923 and developed
symptoms of EV in early childhood. Persistent lesions spread
from the neck and hands to the patient’s legs. After the age of 52
yr, P14 developed several actinic keratoses, SCCs, and basal cell
carcinomas that were clinically well managed by a combination
of surgery and topical treatment. P14 died from natural causes at
the age of 91 yr. HPV5 was identified by PCR amplification from
specimens obtained from these two patients.
Kindred D (P15; Figs. 1 A and S1; Tables 1, S1 B, S4, and S5)
P15 (D.iv.2; Fig. 1 A) was born to consanguineous parents from
Switzerland, and her phenotype was recently described in a
case study (Imahorn et al., 2017). Familial consanguinity was
confirmed by a high inbreeding coefficient determined with an
SNP 6.0 array (Table S5). P15 developed first lesions during early
childhood (Fig. S1 B). She was treated for several carcinomas in
situ (Bowen type) and SCCs from the age of 54 yr onwards. HPV5
was detected by PCR amplification and Sanger sequencing. This
patient has no immunological abnormalities of T cells, B cells, or
NK cells (Table S1 B). She was also extensively phenotyped for
skin-homing total CD3+, CD4+, and CD8+ cells and T cell subsets
(CLA+, CLA+CCR4+, CLA+CCR10+, and CCR10+), none of which displayed any marked difference relative to five unrelated healthy
donors (Table S4).
Kindred E (P16–P19; Figs. 1 A and S1 C; Tables 1 and S5)
P16 (E.iv.4; Fig. 1 A), P17 (E.iv.6; Fig. 1 A), and P19 (E.iv.10; Fig. 1 A)
were first described in a case study (Saka et al., 2009). In brief,
P16–P19 were born to consanguineous parents from Togo. Familial consanguinity was confirmed on the basis of a high inbreeding coefficient in an SNP 6.0 array analysis (Table S5). P16
first developed papules on her face at the age of 7 yr, and these
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lesions subsequently disseminated over her entire body. She was
diagnosed at the age of 15 yr and died at the age of 21 yr from a
pulmonary metastasis secondary to the development of multiple
SCCs on areas of the skin exposed to the sun. P17 first developed
papules on her face at the age of 5 yr, and these lesions subsequently disseminated over her entire body. P18 was not included
in the initial case study. Only limited information about her clinical characteristics is available. She died in 2013 after an episode
of fever. P19 is currently 14 yr of age and was first presented with
disseminated skin lesions at the age of 2 yr (Fig. S1 C). P16, P17,
and P19 had normal blood counts and renal and hepatic functions
and were confirmed to be HIV negative. Histological analysis
confirmed the presence of the pathognomonic cytopathic effect
in a lesional skin biopsy. It was not possible to type the causal
HPV due to infrastructure-related difficulties.
Kindred F (P20–P24; Figs. 1 A, S1 D, and S2; Tables 1 and S5)
Two patients, a 47-yr-old man and his 22-yr-old daughter, were
referred to the Dermatology Department of the Tehran University of Medical Sciences for the evaluation of a chronic condition
that had begun during childhood. Similar presentations were observed in other family members, with five in total all born to consanguineous parents, suggesting the presence of an AR Mendelian
disorder in the extended family. All patients were healthy at birth,
but they developed cutaneous lesions resembling widespread flat
warts and thin plaques from the ages of 1–3 yr onwards. Multiple
hyperpigmented plaques were observed on the skin of the male
patient. These plaques had an occasionally verrucous surface and
displayed ulceration and scaling with raised pearly borders. Three
excisional biopsies of the ulcerated plaques revealed the presence of islands of infiltrative malignant cells in the dermis with
palisading basaloid cells and polygonal squamous differentiation
with areas of keratinization and intercellular bridges consistent
with basosquamous carcinoma. The patient also had numerous
slightly raised brown papules and plaques on the face, neck, arms,
chest, and back of the hands, some coalescing into larger plaques
with a papillomatous surface. Microscopic evaluations of these lesions revealed hyperkeratosis and acanthosis, with keratinocytes
displaying coarse keratohyaline granules, perinuclear halos, and
a blue-gray pallor characteristic of EV. A jaw x-ray (orthopantogram) was performed to evaluate jaw keratocysts and other abnormalities suggestive of nevoid basal cell carcinoma syndrome,
which were found to be within normal limits. The index case and
one of his affected siblings were positive for HBsAg, and both reported long-term hepatitis B infection and liver cirrhosis. The
female patient had numerous erythematous or hyperpigmented
papules with a flat surface, minimal scaling, and irregular borders
on the face, neck, hands, and arms. Flat pink macules and larger
patches with fine scales were present on the chest and upper
arms. Biopsy of the lesions revealed pathological features typical of EV warts with minimal papillomatosis and hyperkeratosis,
viral cytopathic effects, and a blue-gray hue.
Genome-wide linkage analysis and inbreeding
coefficient determination
Genome-wide linkage analysis was performed essentially as
previously described (Grant et al., 2011) but with minor modiJournal of Experimental Medicine
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fications. 22 members of kindred A, P14, P15, and six members
of kindred E were genotyped with the Affymetrix Genome-wide
Human SNP array 6.0. P10 was genotyped with the Affymetrix
Genome-wide Human Mapping 250K, and P11 was genotyped
with the Affymetrix CytoscanHD array. Four members of family F were genotyped with the Illumina Infinum Global Screening Array (642,824 SNP markers) using 200 ng genomic DNA
in accordance with the manufacturer’s instructions (Illumina).
Genotypes were called with the Power Tools Software Package
(Affymetrix), and Chromosome Analysis Suite Software was
used for P11. SNPs presenting more than one Mendelian inconsistency were discarded. SNPs were further filtered with population-based filters with PLINK software (Purcell et al., 2007)
according to the ethnicity of the kindred. A subset of markers
common to the three arrays and optimized to decrease their
linkage disequilibrium (LD) was used for parametric multipoint
linkage analyses in MERLIN (Abecasis et al., 2002) for kindreds
A1, A2, B, D, E, and F, considering founders to be second-degree
relatives and assuming AR inheritance with complete penetrance
and a deleterious allele frequency of 10−4. The family founders
and unrelated individuals from HapMap CEU, MEX, and YRI
were used to estimate allele frequencies for kindreds B and D, A1
and A2, and E, respectively, and to define linkage clusters with an
r2 threshold of 0.4. For kindred F, we estimated allele frequencies
from an unrelated Iranian cohort of 82 healthy individuals.
We estimated the inbreeding coefficient F by Markov processes to model homozygous states throughout the genome
according to the FEstim method (Leutenegger et al., 2003). We
used the FEstim_SUBS method to minimize LD between SNPs
as recommended in a previous study (Gazal et al., 2014) for the
random extraction of sparse markers at 0.5-cm intervals to create 100 submaps. This strategy does not require the estimation
of LD scores for the data, and F is estimated by calculating the
median value of the estimates obtained from the different maps.
FSuite v1.0.3 software was used to calculate FEstim and to infer
the degree of parental consanguinity for each individual from the
genome-wide human SNP array data (Gazal et al., 2014).
WES
The method used for WES has been described previously (Bolze
et al., 2010; Byun et al., 2010). Briefly, genomic DNA extracted
from the patients’ blood cells or LCLs was sheared with a Covaris
S2 Ultrasonicator. An adapter-ligated library was prepared with
the Paired-End Sample Prep kit V1 (Illumina). Exome capture was
performed with the SureSelect Human All Exon kit (50- or 71-Mb
version; Agilent Technologies). Sequencing was performed on an
Illumina Genome Analyzer IIx (Illumina) generating 72- or 100base reads. For kindred F, DNA was extracted from peripheral
blood samples by the salting out method. DNA concentration
was measured with a Qubit 2.0 fluorimeter (Thermo Fisher Scientific). WES was performed for probands and affected family
members. Exons and flanking intronic regions of ∼20,000 genes
(45 Mb; 98% of consensus coding sequence exons) were captured
with the Illumina TruSeq Exome Enrichment Kit and sequenced
on a NextSeq 500 instrument (Illumina). We used a BWA-MEM
algorithm (Li and Durbin, 2009) to align the sequences with the
reference human genome sequence (hg19build). Downstream
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processing was performed with the Genome Analysis Toolkit
(GATK; McKenna et al., 2010), SAMtools (Li et al., 2009), and
Picard Tools (http://broadinstitute.github.io/picard/). Substitution calls were made with GATK UnifiedGenotyper, whereas
indel calls were made with SomaticIndelDetector V2. All calls
with a read coverage of <2× and a Phredscaled SNP quality of
<20 were filtered out. Single-nucleotide variants were filtered
on the basis of dbSNP135 (http://www.ncbi.nlm.nih.gov/SNP/)
and 1000Genomes (http://www.internationalgenome.org) data.
All variants were annotated with ANNOVAR (Wang et al., 2010).
The sequence data are available from the Sequence Read Archive
website under accession number SRP151153. All variant calls with
a variant quality <200, depth of coverage <5, and mapping quality <40 were filtered out. Only exonic and splice variants were
retained, and synonymous and heterozygous variants were subsequently removed. Single-nucleotide variants with a MAF of
>0.1% in public databases were then excluded, given the rarity
of EV. This process identified 26–56 variants per patient.
Sanger sequencing of genomic DNA
Genomic DNA samples from patients and their relatives were
used as a template for the amplification of 300–600-bp regions
encompassing the mutation by PCR with site-specific oligonucleotides. Amplicons were sequenced with BigDye Terminator
technology on an ABI 3730 DNA sequencer. Lasergene Suite
and SnapGene were used for sequence analysis (DNASTAR
and SnapGene).
IHC
Briefly, skin punch biopsy specimens (6 mm in diameter) were
obtained from waste skin removed from individuals undergoing
abdominoplasty (two individuals). Biopsy specimens were frozen
in optimal cutting temperature compound (Sakura) and stored at
−80°C. Tissue sections were air dried, fixed with acetone, blocked
by incubation with 10% normal serum, and stained with the anti-CIB1 monoclonal antibody UN-2 (Naik et al., 1997) or an IgG1-κ
isotype control (Sigma-Aldrich) at a concentration of 13 µg/ml
overnight at 4°C. Tissue sections were thoroughly washed and
incubated with biotin-labeled horse anti-mouse secondary antibody (Vector Laboratories) for 30 min at room temperature. The
slides were then treated with 0.3% H2O2 and washed, and the
staining signal was amplified with avidin–biotin complex Vectastain (Vector Laboratories), activated with 0.015% H2O2, and
developed with a 5% solution of the chromogen 3-amino-9-ethylcarbazole (Sigma-Aldrich) for ∼20 min. IHC was performed on
specimens from four healthy donors.
RNA sequencing
Total RNA was isolated from primary keratinocytes from P5 and
P14, two healthy donors (control 1 and control 2), and cells from
P5 stably expressing GST as an irrelevant protein or complemented with an untagged CIB1 construct. Total cellular mRNA
was prepared for sequencing with the NextSeq 500/550 High
Output v2 kit. We generated 75-bp single reads on a NextSeq
500. Reads were mapped onto the reference genome with STAR
v2.5.3a (Dobin et al., 2013). A genome index specific to our data
was first created, and the single-end reads were then aligned
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in a two-pass strategy. In this strategy, new splicing junctions
are first detected and used for the final mapping. Read counts
were obtained for each gene with HTSeq v. 0.9.1 (Anders et al.,
2015). Gene expression levels were estimated with Transcripts
Per Kilobase Million (TPM). TPM takes the size of each sample
library and gene lengths into account to assess expression levels
(Conesa et al., 2016). Statistical analysis was performed with R
v.3.2.3 (The R Foundation, 2015). Gene expression profiles are
represented as the log(fold change) in expression values between
two different groups.
RT-qPCR
Human tissue
RNA was isolated from LCLs, primary keratinocytes, and
HEK293T cells with the RNeasy mini kit and from whole blood
with the PaxGene blood RNA kit (QIAGEN). Reverse transcription
was performed with the SuperScript III first-strand synthesis
system and oligo(dT) primers according to the manufacturer’s
protocol (Thermo Fisher Scientific). RT-qPCR was then performed with TaqMan assays using exon-spanning probes for CIB1
(Hs01089679_m1), EVER1/TMC6 (Hs00273164_m1), or EVER2/
TMC8 (Hs00380060_m1; Thermo Fisher Scientific) with normalization against GAPDH (4310884E), 18S (Hs99999901_s1), or
RNaseP (4403326) as housekeeping genes by the ΔCT method.
Data are represented as fold changes and were analyzed with the
ΔΔCT method and comparison with an untreated control sample.
The data shown are the means of three experiments.
Cell lines and primary cell isolation
HEK 293T cells were obtained from ATCC (CRL-3216). PBMCs
were isolated by Ficoll-Hypaque density centrifugation (Amersham Pharmacia Biotech) from cytopheresis or whole-blood
samples obtained from healthy volunteers and patients, respectively. EBV-immortalized LCLs (EBV-B cells) were obtained as
previously described (Dupuis et al., 2001). Primary keratinocyte
isolation: Punch biopsy specimens from the inner upper arm
were washed three times with serum-free DMEM supplemented
with 50 µg/ml gentamycin. They were then treated with dispase
(354235; BD) at 4°C overnight. The following day, dermis and
epidermis were separated manually and treated with Accutase
(A6964; Sigma-Aldrich). The epidermis was then cut into pieces
and wounded to obtain basal keratinocytes, which were cultured
as described below.
Cell culture and transfection
HEK293T and HaCaT cells were maintained in DMEM supplemented with 10% FBS. LCLs were maintained in RPMI 1640
supplemented with 10% FBS. Primary keratinocytes were maintained on mitomycin-C–inactivated (10 µg/ml; 3 h) MEF 3T3-J2
feeder cells in complete Green medium (DMEM/Ham’s F12 in a
2:1 ratio supplemented with 10% FBS, 180 nM adenine, 10 ng/ml
EGF, 0.4 µg/ml hydrocortisone, 8.47 ng/ml cholera toxin, 5 µg/
ml insulin, 1.36 ng/ml triiodothyronine, and 10 µM ROCK inhibitor Y-27632). Transfections were performed with XtremeGENE
9 (Roche), FuGENE6 (Promega), Lipofectamine 2000 (Thermo
Fisher Scientific), or Lipofectamine LTX (Thermo Fisher Scientific) in accordance with the manufacturer’s instructions.
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Plasmids
Myc/DDK-tagged pCMV6-entry expression plasmids for EVER1/
TMC6, EVER2/TMC8, CIB1, HPV5 E1, E2, E6, and E7 as well as
HPV16 E1, E2, E5, E6, and E7 were obtained from Origene. An
HA-tagged CIB1 expression construct was generated by inserting
the CIB1 expression cassette from pCMV6-entry into pcDNA3.1
between the BamHI and EcoRI sites. CIB1 was amplified by PCR
with the primers 5′-ATTAGGATCCGCCACCATGGGGGGCTCGGG
CAGTCGC-3′ and 5′-TCGAGAATTCTCAAGCGTAATCTGGAACAT
CGTATGGGTACAGGACAATCTTAAAGGAGC-3′. DDK-tagged
pcDNA3.1+ expression constructs for CRPV E8 and HPV4 E8 were
generated by inserting the E8 ORF (NCBI Reference Sequence
NC_001541) amplified from the CRPV reference genome with 5′ATTAGGATCCGCCACCATGgactacaaggacgacgatgacaagGGACCT
GCAGAGACTGC-3′ and 5′-tcgagaattcTTAATCTTCTTCCGCAAA
CTG-3′ primers between the BamHI and EcoRI sites and restriction cloning the purified synthesized codon-optimized HPV4
(gi|9626597) E8 ORF (from IDT) using the BamHI and EcoRI sites.
Lowercase letters denote restriction sites.
We generated the pLZRS-IRES-ΔNGFR (de Paus et al., 2013;
Martinez-Barricarte et al., 2016) expression plasmids for EVER1/
TMC6 and EVER2/TMC8 with the cold fusion cloning kit (System
Bioscience) in accordance with the manufacturer’s instructions
after linearization with EcoRI. The Myc/DDK-tagged expression cassettes were amplified by PCR from the abovementioned
pCMV6 entry clones with the following primers: EVER1, 5′-ATT
TAAATTCGAATTATGGCCCAGCCACTGGC-3′ and 5′-AGGCCTGCA
GGAATTTTAAACCTTATCGTCGTCATCCTTGTAATCCAGGATATC
ATT-3′; and EVER2, 5′-ATTTAAATTCGAATTATGCTGCTGCCG
CGG-3′ and 5′-AGGCCTGCAGGAATTTTAAACCTTATCGTCGTC
ATCCTTGTAATCCAGGATATCATT-3′. The integrity of all expression cassettes was confirmed by Sanger sequencing.
Retrovirus production and transduction
Retroviruses containing EVER1- or EVER2-encoding or empty
vectors were produced with the pLZRS-IRES-ΔNGFR constructs
described above in Phoenix A cells as previously described
(Martinez-Barricarte et al., 2016). Freshly harvested retroviruses were used to infect LCLs from a healthy WT control and
EV patients with EVER1 D576* m/m, EVER2 T150M fs*3, or CIB1
I156D fs*5. Cells were grown and purified as previously described
(Martinez-Barricarte et al., 2016) but in RPMI 1640 supplemented
with 10% FBS as the culture medium. Flow cytometry confirmed
that the transduced and selected populations were >95% pure.
Immunoblotting and immunoprecipitation
Cells were lysed by incubation in radioimmunoprecipitation
assay (RIPA) buffer supplemented with the inhibitors aprotinin,
NaF, N-ethylmaleimide, Na3VO4, and leupeptin for 30 min on ice,
and the resulting lysate was then cleared. For immunoprecipitation, 10% of the lysate was set aside as the input control. Cleared
lysates were incubated with 1 µg of the indicated antibodies
(FLAG, HA, GFP, or an Ig control) at 4°C on an overhead tumbler
for 2–16 h. Protein A–coupled magnetic Dynabeads (50 µl from a
stock solution; Thermo Fisher Scientific) were added, and antibody-bound protein was captured from the lysate by incubation
for 1 h at 4°C on an overhead rotator. Beads were washed three
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to five times with 200 µl lysis buffer, resuspended in 100 µl lysis
buffer, and transferred to new reaction tubes to prevent the coelution of protein bound nonspecifically to the wall of the tube.
The beads were resuspended in 25–50 µl 2× Laemmli buffer and
boiled at 95°C for 5 min. Samples were subjected to standard SDSPAGE in Mini-Protean TGX 4–20% gels (Bio-Rad Laboratories),
and the resulting bands were transferred onto polyvinylidene
difluoride membrane by semidry transfer for 30–40 min at 200
mA and 25 V per gel. The primary antibodies used were specific
for CIB1 (raised against amino acids 24–43 [9, 11]), the HA epitope
(HA.11-16B12; Covance), the FLAG epitope (M2; HRP coupled or
unlabeled; Sigma-Aldrich), IkBa (L35A5), pIkBa (5A5), and p100/
p52 (18D10; Cell Signaling Technology), GAPDH HRP-coupled
(FL-335), pFAK (2D11), and FAK (D-1; Santa Cruz Biotechnology,
Inc.), vinculin (VIN-11-5; Sigma-Aldrich), GFP (JL-8; Takara Bio
Inc.), and actin (137CT26.1.1; Abgent). We used normal rabbit and
mouse IgG (Santa Cruz Biotechnology, Inc.) as immunoprecipitation controls. The secondary antibodies used were HRP-coupled anti-mouse IgG and anti-rabbit IgG (GE Healthcare) or
anti-chicken IgY (Jackson ImmunoResearch Laboratories, Inc.).
Antibody binding was detected by enhanced chemiluminescence
with hyperfilm ECL or an RGB 600 Imager (GE Healthcare). The
data shown are representative of at least three independent experiments unless too little material was available. See the figure
legends for details.
Immunofluorescence, PLA, and microscopy
Primary keratinocytes were plated on poly-L-lysine–coated coverslips and transfected as indicated above. The cells were fixed by
incubation with 4% PFA 24 h after transfection, permeabilized,
and blocked by incubation in 0.2% Triton X-100, 3% BSA, and
10% normal serum, and then they were incubated overnight with
the primary antibody. The antibodies used were directed against
the FLAG (anti-DDK; Origene) and HA epitopes (Sigma-Aldrich)
and were used at a dilution of 1:500. The secondary antibodies
used were Alexa Fluor 488– or 568–conjugated goat anti-mouse
or anti-rabbit IgG (Thermo Fisher Scientific) at a dilution of
1:500. Cells were counterstained with DAPI (0.5 µg/ml). Coverslips were mounted on slides in Prolong Antifade Gold (Thermo
Fisher Scientific). Images were acquired with a DeltaVision
Image Restoration microscope (Applied Precision Ltd.) using a
60× oil-immersion objective and 0.24-µm steps. Images were
deconvoluted with SoftWoRx software. Deconvoluted z stacks
were subjected to automated image and colocalization analysis
with Imaris software (Bitplane). Representative data from three
independent experiments are shown. For focal adhesion analysis,
primary keratinocytes were plated on fibronectin-coated (10 µg/
ml; Corning) coverslips, to which they were allowed to adhere for
24 h. Cells were fixed with 4% PFA, permeabilized with 0.3% Triton X-100, blocked in 5% normal serum and 0.3% Triton X-100,
and incubated overnight with the primary antibody. The antibodies used were directed against vinculin (VIN-11-5; Sigma-Aldrich) and pFAK (44-624G; Thermo Fisher Scientific), and they
were used at a dilution of 1:500. The secondary antibodies used
were Alexa Fluor 488–conjugated goat anti-mouse or anti-rabbit
IgG at a dilution of 1:500–1,000 (Thermo Fisher Scientific). Cells
were counterstained with Alexa Fluor 568–phalloidin (1 U phalde Jong et al.
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lotoxin/slide; Thermo Fisher Scientific) and DAPI (0.5 µg/ml).
Images were acquired with an AxioObserver.Z1 epifluorescence
microscope (ZEISS) equipped with an ORCA-ER camera (Hamamatsu Photonics) and an ApoTome.2 (ZEISS) with a 40× 1.4 NA oil
immersion objective in 0.24-µm steps with Zen software (ZEISS).
Z stacks were subjected to automated image analysis and surface
detection with Imaris software. Focal adhesions were defined as
vinculin- or pFAK-stained surfaces with a volume >0.002 mm3
within the lower half of the z stack. The parameters analyzed
included volume, fluorescence intensity, and morphology (measured as ellipticity). Values were normalized relative to the total
number of surfaces detected to obtain a mean per detected surface structure. The data shown are the mean and SD of three experiments with eight data points per set. For PLAs, HaCaT cells
were transfected with CIB1-HA or the indicated myc-DDK–tagged
HPV5 and HPV16 E ORF plasmids alone or in combination. Cells
were transferred to poly-L-lysine–coated coverslips after 24 h.
They were allowed to adhere for another 24 h and were then
fixed in ice-cold acetone. Duolink PLA (Sigma-Aldrich) was performed in accordance with the manufacturer’s instructions with
anti-rabbit HA (Sigma-Aldrich) and anti-mouse DDK (Origene)
antibodies at a dilution of 1:400 and then were incubated overnight at 4°C with the cells. Duolink In Situ Detection Reagents Red
was used for visualization.
Reporter gene assay
HEK293T cells were cotransfected with the indicated plasmids
and pMRE-GFP, a GFP reporter construct driven by four copies
of a MRE 5′-TGCACTC-3′ (provided by W. Schaffner, University
of Zurich, Zurich, Switzerland). This element is activated by the
zinc-dependent metal transcription factor 1 (MTF-1). After 24 h,
cells were stimulated with PMA/ionomycin (10 ng/ml and 50 ng/
ml; Sigma-Aldrich) or ZnSO4 (100 µM) overnight. The next day,
cells were stained with 1 µg/ml DAPI to exclude dead cells, and
fluorescence was acquired with an LSRII flow cytometer (BD).
Results are shown as the relative response ratio (RRR) calculated
as RRR= 100% × (sample − negative control)/(positive control −
negative control). Untreated mock-transfected cells served as the
negative control, and untreated vector-transfected cells served as
the positive control. The data shown are the mean and SD of three
independent experiments.
Determination of absolute free zinc levels and zinc kinetics
Labile zinc levels in LCLs and keratinocytes were determined
by flow cytometry as previously described (Haase et al., 2006).
Briefly, cells were loaded with the zinc-specific fluorescent
probe FluoZin-3 (1 µM; Thermo Fisher Scientific) for 30 min at
room temperature. Samples were either left untreated (F sample) or were treated with ZnSO4 and the zinc ionophore pyrithione/2-mercaptopyridine N-oxide (referred to as Fmax; 100 µM
and 50 µM; Sigma-Aldrich) or the zinc chelator TPEN (Fmin;
100 µM; Sigma-Aldrich). All samples were stained with DAPI
(0.5 µg/ml) to exclude dead cells. Fluorescence was recorded on
an LSRII flow cytometer. The concentration of intracellular labile zinc was calculated from the mean fluorescence according
to the formula [Zn] = KD × ([F − Fmin]/[Fmax − F]). The dissociation constant of the FluoZin-3/zinc complex is 15 nM. The data
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shown are the means of three independent experiments for LCLs
and the mean and SD of three independent experiments for keratinocytes. For zinc kinetic measurements, LCLs were stained
with FluoZin-3 (1 µM; 30 min at room temperature) in HBSS
(Thermo Fisher Scientific) and then allowed to rest for 60 min
at room temperature. Fluorescence was recorded on a VICTOR
plate reader (PerkinElmer). Baseline fluorescence was monitored
every 60 s for 10 min. Cells were then sequentially loaded with
ZnSO4 (100 µM), the calcium chelator BAPTA (25 µM; Sigma-Aldrich), and the zinc-specific chelator TPEN (200 µM). In each set
of conditions, fluorescence was determined every 60 s for 10–20
min. BAPTA treatment ensured the specificity of the zinc signal.
Unstained cells were used to correct values for background fluorescence. The data shown are the mean and SD for three independent experiments.
Flow cytometry/immunophenotyping
Whole blood was either processed directly or used for the isolation of PBMCs on a Ficoll density gradient. The PBMCs obtained
were then either processed directly or frozen for future use. We
lysed the red blood cells by incubating 100 µl fresh whole blood
with fluorophore-conjugated antibodies for 20 min and then with
FACS lysing solution (BD) for 10 min at room temperature. The
antibodies used for staining were CD45-FITC, CD3-PE-Cy7, CD19PE-Cy7, CD4–Pacific Blue, CD14-V450, CD8-PE-Cy5, CD8-V450,
or CD16-CD56-PE, CD45RA-FITC, CCR7-PE, and CD3-APC. Fluorescence was measured on a FACSCanto II flow cytometer (BD).
Frozen PBMCs were thawed, washed, and incubated with Zombie
UV viability dye (BioLegend) and then with fluorophore-conjugated antibodies in brilliant stain buffer (BD) for 30 min. The
antibodies used were CD45RO-BV421, CD4-BV605, CCR4-BV421,
CLA–Alexa Fluor 647, CD45RA–Alexa Fluor 488, CCR7–Alexa
Fluor 647, CD8-PE-Cy7, HLA-DR-FITC, CD16-APC-Cy7, CD20-PE
(BioLegend), CD3-PerCP-Cy5.5, CCR10-BB515, and CD56-APC
(BD). Fluorescence was measured on an LSRII flow cytometer.
Data were analyzed with FlowJo software (v.9.8.3; Tree Star).
Whole-blood experiments were performed for two patients (P3
and P5). Frozen PMBCs from healthy donors (n = 5), WT family
members (n = 5), healthy heterozygous family members (n = 4),
and patients (n = 5; P1–P4 and P15) were used. The data were obtained in a single–time point experiment.
T cell proliferation assay
Freshly isolated PBMCs were loaded with carboxyfluorescein
succinimidyl ester (5 µM; Invitrogen) for 5 min, washed, and
plated at a density of 1 × 105 cells/ml in RPMI 1640/10% FBS
supplemented with 2% penicillin/streptomycin on plates coated
with anti-CD3 antibody (5, 2.5, or 1.25 µg/ml; clone UCHT1). Cells
were then stimulated with anti-CD28 antibody (1 µg/ml; clone
ANC28/5D10) for 3 d at 37°C in a humidified incubator under an
atmosphere containing 5% CO2. Cells were harvested and processed for flow cytometry by incubation with an APC-conjugated
anti-CD3 antibody in flow cytometry buffer for 20 min. Fluorescence was measured on a FACSCanto II flow cytometer. The
data were analyzed with FlowJo software using the proliferation
analysis tool. The parameters displayed included proliferation
index (the total number of divisions divided by the number of
de Jong et al.
CIB1 deficiency in epidermodysplasia verruciformis

cells entering division), division index (the mean number of cell
divisions undergone by a cell from the original population), and
percent division (precursor frequency). The data shown were
obtained in a single–time point experiment on specimens from
two patients (P3 and P5) and two controls processed in parallel.
Scratch wound healing assays
Primary keratinocytes were plated on fibronectin-coated (10
µg/ml; Corning) glass-bottomed six-well culture plates (MatTek). The cells were allowed to adhere to the plates overnight,
and the resulting monolayer was then scratched with a pipette
tip. Wound closure was monitored every 20 min for 16 h with an
inverted Andor-driven spinning-disk confocal system equipped
with a Zyla 4.2 (Andor Technology) camera in brightfield conditions with a 10× 0.3 NA air objective. During imaging, cells
were maintained at 37°C under an atmosphere containing 5%
CO2. The images were subjected to automated analysis with the
MiToBo plugin in ImageJ (National Institutes of Health) to determine the cell-free area, which was normalized relative to the
initial cell-free area and expressed as a percentage. The start and
endpoint images were also manually analyzed by measuring the
total cell-free area with the freehand tool. The data shown are the
means for two to three experiments with at least six data points
per experiment.
Large-scale protein purification and mass
spectrometry analysis
For identification of the cellular partners interacting with CIB1,
we transfected HEK239T cells (∼107 cells per 10-cm dish) in 10
dishes with 12 µg plasmid encoding CIB1-FLAG or ORF75-FLAG
(control) in the presence of GenJet transfection reagent (SignaGen). 36 h later, the cells were lysed with RIPA buffer supplemented with protease inhibitor cocktail and centrifuged
at 13,000 rpm for 20 min at 4°C. Lysates were precleared with
100 µl Sepharose 4B (Sigma-Aldrich) to remove cell debris and
then were mixed with a ∼50% slurry of anti-FLAG M2 Affinity Gel (Sigma-Aldrich) and incubated for 4 h at 4°C. The beads
were thoroughly washed in lysis buffer, and the bound proteins
were eluted by heating samples in 2× Laemmli SDS sample buffer for 5 min at 95°C before separation by electrophoresis on a
NuPAGE 4–12% Bis-Tris gradient gel (Thermo Fisher Scientific).
The coimmunoprecipitated proteins were stained by incubation
with colloidal Coomassie solution (0.02% Coomassie Brilliant
Blue G-250, 5% aluminum sulfate-(14–18)-hydrate, 10% ethanol,
and 8% orthophosphoric acid [85%]; Kang et al., 2002) at room
temperature overnight. Bands specifically present in the CIB1FLAG sample but absent from the ORF75-FLAG sample were
excised and analyzed by ion-trap mass spectrometry at the Taplin Biological Mass Spectrometry Facility (Harvard Medical
School, Boston, MA).
Gene ontology analysis
Gene ontology analysis was performed according to the PAN
THER classification system release 20170413 (Mi et al., 2013) with
the overrepresentation test and the Reactome version 58 (release
20161207) against the Homo sapiens database. Bonferroni correction for multiple testing was applied. 239 mapped hits were run
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against 21,042 database entries. The data are represented as fold
enrichments, with P values <0.05 considered significant.
Statistical analyses
Statistical analyses were performed with Prism 5.0 (GraphPad
Software).
Online supplemental material
Fig. S1 depicts photographs of the clinical EV manifestation of
the studied patients. Fig. S2 depicts the results of GWL analysis
and whole-exome filtering performed on the studied patient cohort and shows chromatographs obtained by Sanger sequencing
that confirmed the mutations identified in CIB1. Fig. S3 shows
qPCR expression data of EV-related genes after interferon treatment of primary human control keratinocytes. Fig. S4 shows
the results obtained by performing mass spectrometry after immunoprecipitation of CIB1 expressed in HEK293T cells as well
as immunofluorescent microscopy and colocalization analysis
of CIB1 and ZnT1 in primary human control keratinocytes.
Table S1 shows the results obtained by immunophenotyping
for the studied patients using flow cytometry. Table S2 shows
the T cell proliferation. Table S3 shows the viral serologies.
Table S4 shows the skin-homing T cell subpopulations. Table
S5 shows the inbreeding coefficient. Table S6 shows the transcriptomic analysis.
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